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Part A: Protocol 
1. Introduction  
1.1. Abstract 
The Autism Spectrum Disorders(ASD) are a group of neurobiological conditions of growing 
prevalence for which there is no known cure. International prevalence studies have determined that 
children and adolescents with ASD are a highly medicated population. This comes to light in the 
context of a paucity of data around the efficacy of commonly prescribed medications. There is no 
data around the prevalence of medication use in the ASD population in South Africa. The aim of this 
study is to determine the prevelance and patterns of medication use in children and adolescents 
with ASD in the Western Cape and to determine the relationship between demographic variables 
and behaviours and medication use. This is a cross-sectional study design; a survey questionnaire 
and the Nisonger Child Behaviour Rating Form (NCBRF) will be utilized to collect the relevant data. 
The study will be conducted at two schools for children and adolescents with ASD in Cape Town. 
Participants will also be recruited from the Autism Action mailing list. Participants will be parents 
and caregivers of children and adolescents between the ages 3 and 18 with a formal ASD diagnosis, 
accessing educational services and residing in the Western Cape. The survey questionnaire will 
collect demographic data, details of all medication currently used, the presence of any comorbid 
medical and psychiatric conditions and information on educational placement. The NCBRF will be 

















1. The prevalence rates of the use of psychotropic medication, over the counter (OTC) 
preparations and special diets are high in children and adolescents with ASD in the Western 
Cape. 
2. Higher levels of problem behaviours predict greater psychotropic medication use. 
3. Increasing age predicts greater psychotropic medication use. 
4. Younger age predicts greater use of special diets and OTC supplements. 
5. Higher income predicts greater access to health care services and therefore greater 
psychotropic medication use. 
1.2. Aim 
To investigate the prevalence and patterns of medication use amongst children and adolescents with 
ASD in the Western Cape. 
1.4.  Objectives 
1. To determine the prevalence of the use of psychotropic medications, OTC preparations and 
special diets in children and adolescents with ASD in the Western Cape. 
2. To describe patterns of psychotropic medication, OTC preparation and special diet use; 
including the dose, prescriber and indications for use. 
3. To determine the categories of health or other professionals prescribing medications, OTC 
preparations and special diets to children and adolescents with ASD. 
4. To determine the relationship between behaviours and psychotropic medication use. 
5. To determine the relationship between age and psychotropic medication use. 
6. To determine the relationship between age and special diets and OTC medication use. 
















1.5 Background and Significance 
The pervasive developmental disorders (PDD) are a group of neurobiological conditions, evident in 
the first few years of life, that follow a chronic course and are characterised by pervasive dysfunction 
in three core domains: reciprocal social interaction, communication and stereotyped behaviours 
(American Psychiatric Association, 2000). The DSM IV (American Psychiatric Association, 2000) 
defines five PDD: Autistic Disorder, Rett’s Disorder, Childhood Disintegrative Disorder , Asperger’s 
Disorder and Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS). The Autism 
Spectrum Disorders (ASD) include Autistic Disorder, Asperger’s Disorder and PDD-NOS. These 
conditions show marked clinical heterogeneity with changing symptomatology relating to 
developmental stage (Seltzer, et al., 2003). 
The prevalence rates of Autistic Disorder vary markedly between epidemiological studies. According 
to the DSM IV, the mean prevalence rate is 5 cases per 10 000 with a range of 2 to 20 cases per 
10 000 individuals (American Psychiatric Association, 2000). Although evidence is lacking, PDD-NOS 
and Asperger’s Disorder appear to be more common (Bernet, et al., 1999). More recent United 
States of American estimates predict that 3 to 6 out of every 1000 children will have autism 
(National Institute of Health, 2009). These figures were concordant with data from studies from 
multiple sites and using vary ng methodologies (Geschwind, 2009). The apparent rise in prevalence 
remains a controversial issue and may be related to improved identification, and not a true rise, in 
incidence (Gurney, et al., 2003). According to the statistics of Autism Western Cape, 1 in 86 South 
African children under the age of 6 is affected by autism and 10 children per week are being 
diagnosed at Red Cross, Tygerberg and Lentegeur Psychiatric Hospitals (Autism Western Cape, 
2009). A 2009 review stated prevalence rates for ASD between 1 per 150 and 1 per 200 individuals 
and rates of 1 per 500 for the diagnosis of strictly defined autism.  
There is no cure for autism, but behavioural and pharmacological interventions are aimed at 















comorbidities. This allows for improved level of functioning and quality of life (Deokar, et al., 2008). 
Dysfunctional behaviours interfere with educational and rehabilitation interventions and can cause 
significant distress (Bernet, et al., 1999). Early identification of ASD and the implementation of 
sustained, appropriate educational and behavioural interventions improves long term clinical 
outcomes (Bernet, et al., 1999) (Tsai, 1999). 
Despite the implementation of educational and behavioural interventions, many individuals remain 
impaired and distressed and the use of pharmacological interventions becomes necessary (Posey, et 
al., 2001). To date, risperidone is the only medication approved by the U.S Food and Drug 
Administration (FDA)for the treatment of problem behaviours, specifically irritability, aggression and 
self-injury, in children with autism (Food and Drug Administration, 2006). Psychotropic medications 
from all classes are currently in use including antidepressants, mood stabilizers, antipsychotics, 
antihypertensives and stimulants. Alternative and more easily obtainable over the counter (OTC) 
treatments such as megadose vitamins, herbal remedies and specialized diets are also used. There is 
minimal data about the long term safety of any of these agents (McCracken, 2005). 
Medication surveys in the field of intellectual disabilities exposed elevated prescribing rates and 
served to guide changes in prescribing practices in the United States of America (Aman, et al., 2003). 
These studies did not specifically address ASD.  
There have been several scientific prevalence studies since 1995 which show that the ASD 
population is highly medicated, and is becoming increasingly medicated (Aman, et al., 1995) (Martin, 
et al., 1999) (Langworthy-Lam, et al., 2002) (Aman, et al., 2003) (Witwer, et al., 2005) (Aman, et al., 
2005) (Oswald, et al., 2007) (Gurney, et al., 2006) (Mandell, et al., 2008) (Esbensen, et al., 2009). This 
body of epidemiological data is growing in parallel with systematic reviews into evidence supporting 
prescribing practices in ASD. These reviews reveal an urgent need for placebo-controlled trials of 















(Palermo, et al., 2004) (Kwok, 2003) (Findling, 2005) (Leskovec, et al., 2008) (Mc Dougle, et al., 2008) 
(Parikh, et al., 2008). 
Most available data on the prevalence of medication use in ASD comes from the United States of 
America. The very first medication prevalence survey was conducted by Rimland in 1988 (Rimland, 
1988). This was an informal survey completed by approximately 4000 parents of autistic children. 
The questionnaire included parental efficacy ratings. Thioridazine was the most commonly used drug 
(n=724), but high dose vitamin B6 and magnesium received the highest ratings for behavioural 
improvement.  
The first scientific study was a point prevalence survey conducted in the Autism Society of North 
Carolina in 1992 and 1993 (Aman, et al., 1995). The questionnaire elicited demographic and 
medication use information, specific data related to epilepsy, as well as parent satisfaction with 
treatment. Of the 838 respondents aged 1 to 82, 33.8% of the sample were taking some 
psychotropic drug or vitamin for autism or associated behavioural or psychiatric problems. If all 
agents, including vitamins, antiepileptics and other physical treatments were included, over 50% of 
the population were medicated. Neuroleptics were the most prevalent group (12.2%) with greater 
use of thioridazine than haloperidol. The next most commonly used drugs in order were: 
psychostimulants (6.6%), anxiolytics (6.3%), antidepresants (6.1%), antihypertensives (4.4%) and 
mood stabilizers (3.9%). Antiepileptic medications were considered as mood stabilizers in the 
absence of comorbid epilepsy. Of the sample, 19.2% were taking vitamins and 13.2% 
anticonvulsants. Age and type of housing (a proxy variable reflecting difficulty in management) were 
found to be independent predictors of psychotropic medication use. 
A further two large point prevalence studies of medication use in individuals with ASD have since 
been conducted in questionnaire form (Aman, et al., 2003) (Langworthy-Lam, et al., 2002). The 
second study was done in the Autism Society of Ohio in 1999 and the third in the Autism Society of 















to assess longitudinal trends and regional effects (Aman, et al., 2005). There were significant 
increases in medication use with time.  
In the second Northern Carolina study, of the 1538 respondents between the ages 3 and 56, 45.7% 
of individuals with autism were taking psychotropic drugs. This increased to 53.1% with the inclusion 
of vitamins and antiepileptics (Langworthy-Lam, et al., 2002). Antidepressants were the most 
commonly used psychotropic medication (21.7% of the sample), followed by antipsychotics (16.8%) 
and stimulants (13.9%). The longitudinal trend was a very large increase in antidepressant utilization 
with significant increases also occuring in antipsychotic, psychostimulant and anitihypertensive 
utilization. Changing patterns were thought to reflect increased physician prescribing of the newer 
selective serotonin reuptake inhibitors (SSRIs) and atypical antipsychotics. The first Carolina study 
had been completed before the introduction of these agents. These medications have greater 
perceived safety as well as a growing body of evidence to support their use (Mc Dougle, et al., 2008) 
(Leskovec, et al., 2008). In keeping with previous findings, greater age and greater severity of autism 
and intellectual disablility predicted psychotropic medication use. Interestingly, younger autistic 
individuals had increased use of autism supplements; possibly because parents of younger indivduals 
seek out more “natural” remedies.  
The Ohio study survey included 417 respondents aged 2 to 46 and findings were consistent with the 
second Northern Carolina study (Aman, et al., 2003). This went against the authors’ original 
hypothesis that there would be less medication use in Northern Carolina because of greater access 
to psychoeducational services.There was significantly greater use of supplements for autism in the 
Ohio group. There were strong demographic variable correlates between all three studies, with 
greater age and level of disability and more restrictive placement being associated with increased 
medication use. 
Psychotropic medication has been investigated in a specific subgroup of individuals with higher 















medication information, data collection included developmental, behavioural and educational 
inventories such as the Autism Behaviour Checklist (ABC). The sample was drawn from children, 
adolescents and adults attending the Yale Child Study Center’s Project on Social Learning Disabilites 
and was therefore not a naturalistic sample. Of 109 children, adolescents and adults, 55% were 
taking psychotropic medications with 29.3% taking more than one medication. These findings reflect 
similar rates to those of the general ASD population. Antidepressants were the most commonly used 
agents (32.1%) followed by stimulants (20.2%) and antipsychotics (16.5%). The high rate of SSRI use 
was again attributed to presciption practices related to limited side effect profile and the perception 
of the “benign” nature of these medications. An added dimension to this study was the inclusion of 
prescribing practices. Medications had been prescribed by general psychiatrists in 58.3% of the 
sample, child psychiatrists in 26.7% and by neurologists and paediatricians in 10%. There was 
marked clinical heterogeneity within the sample, with many symptoms that were unrelated to the 
core features of autism being treated pharmacologically. Of note were the high rates of depression 
and anxiety symptoms. 
The above studies are all point prevalence studies which are reliable in extracting information about 
current medication use, but limited in reflecting the use of medications that are not constantly 
administered. This aspect was addressed in a study by Witwer and Lecavelier where information was 
obtained from 353 participants regarding 1 year rates and patterns of medication use (Witwer, et al., 
2005). The aim of the study was to focus on the younger population with the inclusion criterion of 
age between 3 and 21 years. Parents also completed the Nisonger Child Behaviour Rating Form to 
identify problem behaviours and the Scale of Independent Behaviour-Revised, which is a 
standardized measure of adaptive behaviour. The one year rates of medication use were found to be 
similar to previous point-prevalence studies, supporting the reliability of point prevalence data. Of 
the subjects, 46.7% had taken at least one psychotropic medication in 1 year, 17.3% some type of 
vitamin and 15.5% were on a specialized diet. There is currently no empiric evidence to support 















psychostimulants (24%), followed by antidepressants (21.2%), antipsychotics (19.5%), alpha agonists 
(10.9%) and mood stabilizers (4.2%). Compared to previous studies, a higher percentage of children 
and adolescents were taking psychostimulants and antipsychotics. Differences in neuroleptics were 
accounted for by the increasing trend of atypical antipsychotic prescribing, due to mounting 
supportive evidence (Mc Dougle, et al., 2008). Methodological differences between the studies were 
also thought to contribute to the higher percentage of respondents having used antipsychotics , as 
children may have been given brief trials of antipsychotics over the year. Stimulant use was thought 
to be higher because of the nature of the age demographic of the sample. Greater age, lower 
adaptive skills and social competence and higher levels of problem behaviour were associated with 
greater medication use. 
The findings of these large questionnaire based surveys are supported by evidence from recent 
cross-sectional telephone (Gurney, et al., 2006) and internet surveys (The Interactive Autism 
Network, 2008). 
A limitation of surveys that utilise parental reporting is that they rely on parent recollections. Several 
studies have addressed this issue by altering methodological design to draw on information from 
various sources of medical records (Oswald, et al., 2007) (Mandell, et al., 2008). With access to large 
databases and without the limitation of non-response, sample sizes tend to be much larger. 
Oswald and others collected data from the 2002 commercial claims and encounters databases of a 
healthcare information company (Oswald, et al., 2007). Their sample included all individuals under 
the age of 21 and information was reviewed regarding demographics, medication use as well as 
inpatient admissions and outpatient visits. Of the 2390 individuals with ASD, 83% had at least one 
drug claim in the last year from 125 medication classes. Of the sample, 57% received psychotropic or 
anticonvulsant medications. This finding is in keeping with point prevalence studies and supports the 
reliablility of the parent survey data. The most common class of psychotropic medication used was 















(15.2%), hypotensive agents (11.9%), hypnotics (5.8%) and benzodiazepines (4.2%). Antidepressants, 
antipsychotics and anticonvulsants showed increasing use with age. A limitation was that this study 
did not include over the counter drugs. Another concern, despite this being a commonly used 
methodology, is that data reflects what prescriptions were filled, and not whether medications were 
actually taken.  
Mandell and others conducted a cross-sectional study of 60641 children with ASD using Medicaid 
claims from 2001 to determine patterns of psychotropic medication use (Mandell, et al., 2008). 
Medicaid is the United States Health care programme for individuals with low incomes and 
resources. It includes individuals with disabilities (Wikipedia, 2009). The study collected 
demographic data, information regarding psychotropic medication use and data on County and State 
characteristics. Of the sample, 56% used at least 1 psychotropic medication during 2001, with 20% of 
these using more than 3 concurrently. Neuroleptics were the most common (31%), followed by 
antidepressants (25%), stimulants (22%), mood stabilizers (21%), anxiolytics (12%) and sedatives 
(3%). Older children were more likely to use medication. Children in foster care had the highest rates 
of use of psychotropic medications. Children who had an inpatient stay were more likely to use 
medication. Differences were found between the ASD, with 61% of children with Asperger’s disorder 
and PDD-NOS taking psychotropic medications and 53% of children with an Autistic disorder 
diagnosis taking psychotropic medications.The proportions of individuals using medications in this 
study could be higher than community based samples, because children accessing Medicaid may be 
more severely affected by autism. 
To date, there has been only one longitudinal study of medication use among individuals with ASD 
(Esbensen, et al., 2009). Esbensen and others examined 286 adolescents (10 years or older) and 
adults over a 4.5 year period. Their findings confirmed the high prevalence rates of medication use 
and the increasing use of medication over time. Initially 70% of individuals were taking psychotropic 















study, 57% took at least one psychotropic medication and 37% took at least one non-psychotropic 
medication. For both types of medication, the number of medications and the proportion of 
individuals taking medications increased with time. Of the nonmedicated individuals in the sample, 
30% began taking medication during the study timeframe. Higher rates of medication use than those 
presented in previous studies can be related to the older age of the sample. Older age has already 
been shown to predict increasing medication use (Aman, et al., 2005). Adolescents have an 
increased risk of developing seizure disorder and psychiatric comorbidity which could explain greater 
medication use with age (American Psychiatric Association, 2000). The longitudinal increases in 
medication use could reflect changes in prescribing practices as discussed above. The authors 
conclude that more people with ASD are taking medications and that more medications are taken 
over time. Individuals who are medicated are likely to stay this way, the pattern being more 
pronounced for psychotropic medications.  
The above studies use various methodologies to explore the prevalence and patterns of 
psychotropic use among idviduals with ASD. Despite the various methodologies, all studies report 
similar findings. This population is highly medicated with increasing use of medications reflecting 
changes in prescibing patterns. Findings from other studies support the reliability of point 
prevalence survey data. 
Despite the growing prevelance of medication use in this population, the evidence base to support 
the prescribing of medications remains small. The pathogenesis of autism is not fully understood and 
as yet there is no cure (Kwok, 2003). First line interventions are behavioural and cognitive strategies. 
These include parental counselling, behaviour modification, special education techniques, sensory 
integration training, speech therapy, social skills training and other communication and social 
interventions (Tsai, 1999) (Bodfish, 2004). Applied behaviour analysis (ABA) has the most supportive 
evidence (Geschwind, 2009). These interventions are most powerful when initiated early on.  















educational interventions. Medication targets distressing and abberant behaviours. This enhances 
the individual’s ability to participate in these programmes and improves the positive response to 
behavioural and cognitive strategies (Tsai, 1999) (Kwok, 2003). 
The core features of autism include impairments in social interactions, impaired communication 
skills and stereotyped patterns of behaviour, interests and activities. Other behaviour symptoms are 
common. According to Tsai, about 60% have poor attention and concentration; 40% are hyperactive; 
43%-88% exhibit morbid or unusual preoccupation; 37% have obsessive phenomena; 16%-85% show 
compulsions or rituals; 50%-89% demontrate stereotyped utterances; 70% exhibit stereotyped 
mannerisms; 17%-74% have anxiety or fears; 9%-44% show depressive mood, irritability, agitation 
and inappropriate affect; 11% have sleep problems; 24 %-43 % have a history of self injury; and 8% 
have tics. These behaviours, which were previously thought to be associated features of autism, are 
now considered to be features of coexisting neuropsychiatric conditions such as attention deficit 
hyperactivity disorder (ADHD), affective disorders, obsessive compulsive disorder and Tourette’s 
disorder (Tsai, 1999). 
Psychiatric comorbidities are common in children with ASD with estimate prevalence rates between 
25%-70% (Geschwind, 2009). A population derived cohort study found high rates of psychiatric 
disorders and frequently multiple disorders in children with ASD. Of the 112 participants, 70% had 
one disorder and 41% had 2 or more disorders. The most common diagnosis was social anxiety 
disorder (29,2%), followed by ADHD (28,2%) and oppositional defiant disorder (28,1%) (Simonoff, et 
al., 2008).  
Clinical dysfunctions in other domains are common in individuals with ASD. These include sensory 
abnormalities, developmental regression, motor signs such as hypotonia and apraxia, gross motor 
delay, sleep disturbance, and gastrointestinal disturbance (Geschwind, 2009). Comorbid medical 















Studies show that neurochemical factors play a role in the pathogenesis of autism. These theories 
provide the rationale for psychopharmacological practices. Tsai summarizes the current 
neurochemical data in his 1999 review .Theories exploring the role of serotonin in autism include 
those of hyperserotonemia, decreased serotonin binding and decreased central serotonergic 
responsivity. Current evidence concerning the role of dopamine in autism is mixed, but dopamine 
agonists have been shown to worsen preexisting stereotypies, aggression and hyperactivity. The 
evidence regarding norepinephrine and epinephrine is also inconclusive with some studies showing 
lower levels in individuals with autism. Neuropeptide studies have shown abnormalities in autistic 
subjects and autistic behaviours resembling opiate-induced behaviours in animals and certain 
behaviours seen in adult oppiate addicts (Tsai, 1999).  
In a recent review, Parikh and others discuss the neurochemical underpinnings of aggressive and self 
injurious behaviours in individuals with autism. Several studies related to the dopaminergic and 
serotonergic systems as well as the noradrenergic and endogenous opioid systems are cited (Parikh, 
et al., 2008). 
There have been a number of reviews in the past decade concerning the evidence base supporting 
prescribing practices in individuals with autism. Out of this body of literature the findings of the most 
recent review by Leskovec and others in 2008 will be discussed here. The overall conclusion is the 
same as that of previous reivews; there are several medications that have been identified as possibly 
being effective in treating autism, but additional clinical trials are much needed (Leskovec, et al., 
2008). This review summarizes the evidence under several behavioural headings which will be used 
in the discussion below.  
Under  ADHD like symptoms evidence is cited for the use of  the psychostimulant methylphenidate. 
This includes a large, double blind placebo control study by the Research Units on Paediatric 
Psychopharmacology (RUPP). Methylphenidate was shown to be efficous but with reduced 















support the use of amphetamines or atomoxetine. There is some evidence for the use of tricyclic 
antidepressants, but major concerns regarding tolerability and cardiac toxicity will limit further 
studies. Further research is indicated for other antidepressants, venlafaxine and bupropion. Future 
research is also recommended for the alpha-2 adrenergic agonists, clonidine and guanfacin and the 
Alzheimer’s disease therapeutics, donepezil, galantamine and memantine before they can be safely 
recommended.  
Aggression, irritability, and self-injurious behaviours are identified as being very disruptive in 
individuals with ASD.There is reasonable evidence, including 3 double-blind, placebo-controlled 
cross-over trials, for the typical antipsychotic haloperidol. Despite this, the high risk of developing 
extrapyramidal side effects make haloperidol and other typical antipscyhotics a less favourable 
choice when compared to the atypical antipshychotics. Clozapine may have a role in treatment 
resistant cases, but there are concerns about the side effect rofile and the need for haematological 
monitoring. Risperidone has been extensively studied and approved by the FDA for the treatment of 
irrritability and aggression. The authors do caution that continued research is needed regarding the 
long term effects. There is limited evidence regarding olanzapine as well as on going concern about 
the propensity for weight gain on this agent. Studies with quetiapine show marked adverse events 
with minimal effectiveness and it is not recommended as first line treatment. There is some 
promising evidence for ziprasidone and aripaprazole but further studies are needed. In another 
recent review on atypical antipsychotics use in children and adolescents with autism by McDougle, 
the atypicals are identified as the emerging firstline management for irritability (Mc Dougle, et al., 
2008). Other agents are also considered in the Leskovec review, but before their use can be 
advocated for aggression and irritability, further studies are recommended. These include the 
anitepileptics topiramate and divalproex sodium as well as the beta-blockers and buspirone. 
Stereotypy and repetitive behaviours are identified as being common in individuals with ASD and 















compulsive disorder. The SSRIs are used for the treatment of OCD and have therefore been the focus 
of several studies. The SSRI fluoxentine demonstrated improvement in open-label trials, but control 
trials are warranted. Fluvoxamine is well tolerated and it appears to be more effective in older 
patients. Sertraline lacks evidence from randomized control studies and studies involving children. 
Paroxetine has been shown to be well tolerated but also evidence from randomized control studies 
is lacking. At the time of this review, citalopram had not been well studied. A recent double blind 
randomized control trial by King and others found citalopram to be ineffective for the treatment of 
repetitive behaviours in children and adolescents with ASD (King, et al., 2009). This trial utilized the 
methodology much needed in medication trials for individuals with ASD. Clomipramine has been 
associated with serious side effects in studies and its use cannot be recommended.  
There is limited evidence in this review for the pharmacological treatment of deficits in social 
behaviours. Further studies are recommended for D-cycloserine, a partial agonist at the N-methyl-A-
apartate glutamate receptor subtype and the cofactor tetrohydrobiopterin. Evidence did not 
support the use of naltrexone the opiate blocker, or the more alternative biological treatments such 
as secretin (a peptide hormone that stimulates pancreatic secretion), vitamins or nutritional 
supplements. 
As stated, the conclusion of this review highlights the fact that medication is being prescribed in the 
absence of sound evidence and that further trials like the recent citalopram trial are much needed. 
To my knowledge, there is no evidence regarding the prevalence and pattern of medication use in 
children with ASD within the South African context. Our unique demographic and social environment 
may reflect patterns that are not in keeping with international trends. This knowledge is vital to 



















The sample for this study will be drawn from two schools for children and adolescents with ASD in 
Cape Town and the database of Autism Action South Africa an organization created by parents to 
serve and support anyone who has daily contact with an ASD person. 
Alpha and Vera schools fall under the administration of the Western Cape Department of Education. 
All learners have a formal diagnosis of ASD. 
Alpha school is located in Woodstock, but a transport service collects children throughout Cape 
Town. There are currently over 60 learners between the ages 4 and 18 attending the school. 
Children who present to the school have a provisional diagnosis of ASD from a doctor. They undergo 
a formal 3 week observation process by a multidisciplinary team. The team consists of a 
psychologist, teacher, speech therapist and occupational therapist. The formal diagnosis of an ASD is 
then given based on the DSM IV criteria (American Psychiatric Association, 2000) and the Childhood 
Autism Rating Scale. 
Vera School is situated in Rondebosch East. There are currently 97 learners attending the school. 
There is a hostel which houses 30 children who cannot attend as day scholars because of transport 
difficulties or behavioural problems. All children have a formal diagnosis of ASD made using the DSM 
IV criteria. Children from throughout the Western Cape attend the school.  
Drawing from a school based sample ensures that children have a formal ASD diagnosis and 
improves response rate. Teachers can also assist parents with literacy problems to complete the 
form which will minimize reporting bias. A limitation of drawing the sample exclusively from the 
schools, is the small size. Therefore, participants will also be recruited from Western Cape members 
of the Autism Action database. This will not only increase sample size, but also access children who 















Autism Action South Africa is an independent organisation. There are currently 300 registered 
members, the majority of whom reside in the Western Cape. All children have a formal ASD 
diagnosis.  
Inclusion criteria for the study will be a formal ASD diagnosis, an age range between 3 and 18 years 
and that the child be attending an educational service and residing in the Western Cape. 
2.2. Measures 
2.2.1. Demographic questionnaire 
Demographic and treament information will be obtained using a questionnaire. See Appendix 1. The 
questionnaire will be available in English and Afrikaans. 
The questionnaire has been been adapted, with permission from author Dr Michael Aman, from that 
used in previous point-prevalence studies (Aman, et al., 2003) (Aman, et al., 1995) (Langworthy-Lam, 
et al., 2002). See Appendix 2.  
The questionnaire consist of four sections demographics, medications, comorbid medical and 
psychiatric illnesses and educational information. Demographic questions include age, gender, race, 
current grade and total gross monthly household income. Parents will be asked to list all medications 
currently being used, including vitamins, over the counter preparations and any special diets. 
Previous studies that reviewed medication use over the previous year did not show different findings 
to point prevalence studies (Witwer, et al., 2005). Asking about current use will improve the 
accuracy of parental reporting. The dose, who prescribed the medication and indication for 
treatment will be included. Prescriber information is relevant in the South African context where 
access to health care providers remains inequitable and there is a shortage of specialists. Other 
general medical illnessess and psychiatric comorbidities will be asked about. The presence of 
epilepsy and current medication used for seizure control will be specifically asked about to ensure 















on the type of educational placement because respondents from the Autism Action database may be 
attending a variety of educational placements. The level of intellectual disability and severity of 
autism has been excluded from the questionnaire because of parental under reporting found in 
previous studies (Aman, et al., 1995). 
2.2.2. Nisonger Child Behaviour Rating Form 
Parents of particpants will also be asked to complete the Nisonger Child Behaviour Rating Form 
(NCBRF). See Appendix 3. This is a standardized intrument for assessing behaviour in children and 
adolescents with intellectual and developmental disabilities (Research Unit on Pediatric 
Psychopharmacology at the Nisonger Center, 2008). The version designed for completion by parents 
will be used. It does not require an interview or observation by an interviewer. The NCBRF has been 
well validated in the United States and the subscales correspond highly with those of the Autism 
Behaviour Checklist (Aman, et al., 1996) (Tasse, et al., 1996). As instructed by the Research Unit on 
Paediatric Psychopharmacology (RUPP), the form will be copied onto blue paper for distribution. The 
NCBRF has 10 social competence items. These are rated on a four-point Likert scale ranging from [0] 
not true to [3] completely or always true. Scoring is distributed on two subscales, Compliant/Calm 
and Adaptive/ Social. The problem behaviour section consists of 66 items. These are rated on a 
Likert Scale from [0] if the behaviour did not occur or was not a problem to [3] if the behaviour 
occurred a lot or was a severe problem. The items are distributed on 6 subscales: Conduct Problem, 
Insecure/ Anxious, Hyperactive, Self-Injury/ Stereotypic, Self-Isolated/ Ritualistic and Overly 
Sensitive. The NCBRF has been translated into Afrikaans and it has been linguistically validated by 
the MAPI Institute (MAPI Institute, 2009). See Appendix 4. The author Dr Aman has given permission 
for the use of the translated version. The schools have agreed to assist parents with literacy 
problems to complete the form.  
An envelope containing an information page (see Appendix 5), consent form (see Appendix 6), 















completion by a parent or guardian. Parents or guardians will then return the forms in confidential 
envelops to the schools. The completed consent form, questionnaire and NCBRF will be collected 
from the schools.  
Parents from the Autism Action database will be emailed with information about the study and be 
invited to participate. Interested parents will email the investigators. Parents whose children are 
attending the schools will be asked not to fill out two separate surveys and to rather complete the 
one sent out from the school. Parents who are willing to participate will be posted the information 
page, consent form, questionnaire and NCBRF. In order to ensure that participants are residing in 
the Western Cape, the survey will only be posted to parents who can provide a postal address within 
the Western Cape. Completed forms can then be posted back to the investigators. 
2.3. Data analysis 
Point prevalence of medication will be determined using frequency counts. If epilepsy is not present, 
anitconvulsants will be grouped as mood stabilizers along with lithium. 
In order to address the hypotheses of this study, medication prevalence will be compared for age, 
household income and the presence of problem behaviours, as identified by subscales on the 
NCBRF. Age will be divided into four ranges; 3-6 years, 7-9 years, 10-12 years and 13-18 years. The 
average monthly household income in South Africa is R 4 415 (Eighty20). Household income will be 
divided into six ranges; R0-R500, R501-R2 500, R2 501-R6 000, R6 001- R16 000, R16 001- R30 000, 
>R 30 001. Categorical variables will be compared using Chi squared tests. 
Any significant difference in prevalence of medication use for the various behaviour subscales of the 
NCBFR will be calculated with the Wilcoxon sum rank test. 
In keeping with other studies, there is a possibility of there being associations between subject 
variables. For example, increasing age may be associated with increased reporting of problem 















multivariate analysis, would therefore be used to assess the significance of the relationships 
between these variables. Age and the NCBRF subscales will be entered as predictors in logistic 
regressions as continuous variables. The categorical variable gender, will be treated as a dummy 
variable. Stepwise logistic regression analyses will be conducted with the major drug groups as the 
dependent variable (i.e., drug present versus absent). At each step of the analysis, a new variable 
will be retained if it predicted drug status at the p<0.05 level (chi sqared). This will indicate a 
significant contribution above variables already in the model. 
A statistician will be consulted when conducting the data analyses and the appropriate software will 
be utilized. 
3. Ethical Considerations  
The survey package includes an information page explaining the purpose of the survey and ensuring 
confidentiality. See Appendix 5. Parents will receive information about the aim and objectives of the 
study and be invited to participate. Participation will be entirely voluntary and participants will not 
be prejudiced in any way if they choose not to participate or if they withdraw consent at a later 
stage. Parents will be asked for their consent to use the information provided for study purposes. 
They will be asked to sign a consent form after they have read and understood the information page. 
See Appendix 6. The choice to use medication is a personal one for each family and can be a 
sensitive issue. Confidentiality of all study participants will be maintained. Consent can be 
withdrawn at any time.  
The study will not be obtaining assent from children under the age of 18, as there will be no direct 
work with children. 
Children who are 18 years old are legally able to give consent; however those with ASD may have 
learning and communication difficulties that interfere with their ability to give fully informed 















be asked to give consent on behalf of their children. If the parent feels that their child is able to 
understand the information sheet the child will be asked to sign an assent form giving persmission to 
use the information about them for study purposes.  
Permission to conduct the survey will be obtained from the principals of both schools and the Board 
of Autism Action South Africa. 
Permission to conduct the survey at the schools will be obtained from the Western Cape 
Department of Education. 
The full research protocol will be submitted to the Departmental Research Committee and 
permission will be obtained from the University of Cape Town (UCT) Ethics Committee. The protocol 
and ethics approval will then be submitted to the post graduate committtee for approval by the 
Faculty of Health Sciences. 
The findings of the research project will be made available to the schools and a presentation of the 
findings will be done for all parents, teachers and interested parties. 
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5. Appendices  
















Prevalence and Patterns of Medication Use in Children and Adolescents with 
Autism Spectrum Disorders in the Western Cape Questionnaire 
 
Please answer as many questions as you can.   
 
1. Identification Data 
 
a) Name of individual with autism: ___________________________________________ 
 b) Date of Birth of individual with autism:  _________Day ________Month __________Year 
 c) Sex of individual with autism(tick):    Male_______      Female_______ 
 d) Ethnicity of individual with autism (tick):     Asian___    Black African___    Coloured ___  Indian ___ White ___   
Other______________ 
 e) Relationship of person completing this form to individual with autism (parent, guardian): 
_________________________________ 
 f) Total gross (before tax deductions) monthly household income (tick):  
R0-R500___   R501-R2 500____   R2 501-R6 000____   R6 001-R16 999___   R16 001-R30 000__   R30 000+ ___ 
 
2.   Medicines 
 
a) Please list all medications, vitamins and supplements CURRENTLY TAKEN by your child in the table below:  
  
 If no medication is taken, please print “N/A”. 
 If medication is taken “Only When Needed”, please print “As Needed” under the “Dosage” column. 
 Please include who prescribed the medication e.g. General Practitioner, Psychiatrist, Paediatrician, 
Neurologist.  
 Please include purpose for which the medication was prescribed e.g. sleep difficulties, problem 
behavior, ADHD. 
 Please include any vitamins, supplements or over the counter medications as well.  
 If you don’t know the answer to a particular question, just write “don’t know” and move on to the 
next question. 
   
Name of Medication or 
Supplement 
Dose per day (mg) Year Started Prescriber Indication 
     
     
     
     
















b) Does your child experience any side effects (unwanted effects) from these medications?  
Yes____ No____ 






c) Is your child on any special diet for autism? 
Yes____ No____ 




3. Other Illnesses 
 





b) Has your child been assessed as having a psychiatric or behavioural diagnosis (ADHD, depression)?  





c) Does your child have epilepsy (fits, seizures)? 
 Yes___ No____ 





4.  Information on Education  
      
a) Does your child attend one of the following education placements? 
(Please tick any that presently apply) 
 __ (I) Regular class in regular school (may include some special provisions in class) 
 __ (II) Special class in regular school (may include those in mainstreaming activities) 































Survey of Medications in Individuals with Autism 
Please answer as many questions as you can.  If you don’t know the answer to a particular question, just 
write “don’t know” and move on to the next question. 
 
 
1. Identification Data 
 
a) Name of individual with autism: _____________________________________ 
           (First)                                (Last) 
 
      b) Date of Birth:  __________month ___________day ___________year 
      c) Sex (check):    ___male  ___female 
      d) Ethnicity:        ___ African American       ___ Caucasian 
          ____Asian        ___Hispanic      ___Other:_________ 
      e) Individual’s weight if known: __________ pounds 
      f) Relation of person completing this form to individual with autism (parent, guardian, brother or      
sister, aunt, etc.): _________________________________ 
      g) Today’s date:  _________month _________day __________year 
 
 
2.   Medicines 
  
a) Please list all medications PRESENTLY TAKEN by this individual on the lines provided at the 
bottom of this page.  If no medication is taken, please print “N/A”.  If medication is taken “Only 
When Needed”, please print “As Needed” under the “Dosage”column. 
If this person is taking any supplements such as vitamins or minerals, on a regular basis, be 
sure to include them as well. 
 
b) In addition, please indicate how satisfied you are with each medication using the following code: 
    1 = very satisfied 
    2 = somewhat satisfied 
    3 = somewhat dissatisfied 
    4 = very dissatisfied 
 
  Name of Medication,                 Dosage per                      Year                    Satisfaction 


























c) Does this person experience any side effects (unwanted effects) from these medications?  If so, please 








   
3.   Information on Seizures, if Relevant: 
  
     Some people with autism have epilepsy (also called fits, spells, or seizures). 
 
a) Does this individual have a seizure disorder (epilepsy)? (Please check) __yes  __no 
 
b)  Does this person take any medication (for example, Depakene, Dilantin, Klonopin,  Lamictal, 
Mysoline, Neurontin, phenobarbital, Tegretol, Zarontin) for control of seizures? (please check) 
       ____yes    ____no (if no, skip to question 4) 
 If yes, please answer the following questions: 
 
c)  How old was the person when the first seizure occurred?       
________years 
 
d) Current frequency of seizures (please check only one): 
 Still has more than a seizure a month 
 Has had more than 3 seizures in the last year, but fewer than one a month 
 Still has seizures, but fewer than 3 in the last year 
 None in the last year 
 None in the last two years 
 None in the last 3 or more years 
 No seizures have ever been observed 
 
e)  Has an EEG (“brain wave”) and/or CAT scan ever been done for this person? (Please check) 
















      If yes, was the EEG:  _____normal  ______abnormal _______ don’t know 
                 was the CAT scan:  _____normal ______abnormal ______don’t know 
 
 f)   Have you ever been told what type of epilepsy this individual has? 
Examples:  grand mal 
        Lennox Gastaut syndrome 
        petit mal (absence) 
        febrile seizure (seizure with fever) 
        temporal-lobe (complex partial) seizure 
        etc. (if so, please list below) 
 
____yes ____no _____don’t know 
 
If yes, please list:  ___________________________________________________ 
 
4.  Could you specify the degree of autism this individual has? 
     ___ mild 
     ___ moderate  
     ___ severe/profound 
     ___ don’t know 
 
 
5.  Does this individual have mental retardation, and if so, what is its severity? 
     ___ no mental retardation 
     ___ mild 
     ___ moderate 
     ___ severe/profound 















6.  Other Medical/Diagnostic Information 
      
     a) Does this individual have medical or other problems (other than epilepsy)? 
         ____ yes    ____ no 
 






7.  Information on Education and Work 
      
      a) Is this individual attending one of the following education or work placements? 
 (Please check any that presently apply) 
 
 __ (I) Regular class in regular school (may include some special provisions in class) 
 __ (II) Special class in regular school (may include those in mainstreaming activities) 
 __ (III) Special school 
 __ (IV) Work (if so, please check the most relevant below): 
  __ sheltered workshop 
  __ supported employment 
  __ employed by the community 
  __ other ______________________________ 
 __ (V) Other (please list) ___________________________________________________ 
 _______________________________________________________________________ 
 

















8.  Housing Arrangements 
 
     a)  What are his/her current living arrangements? (please check one) 
  __ living with family (including adoptive or foster parents) 
  __ living independently 
  __ living in partially sheltered situation (e.g., supported living, group home) 
  __ living in sheltered environment (e.g., nursing home or institution) 
  __ other (please describe) ____________________________________________ 
 
9.  Parents’ Education (Please circle) 
Mother Father 







a. High school not completed 
b. Graduated from high school 
c. Technical school, qualification obtained 
d. Attended college, did not graduate 
e. Graduated from college 
f. Graduate or professional degree (e.g., law) 
 
Thank you for taking part in this study!  When finished, please use the envelope provided and return the 
questionnaire.  If the envelope gets lost, please mail to: 
 Michael Aman, Ph.D. 
 The Nisonger Center 
 The Ohio State University 
 1581 Dodd Drive 















5.3. Appendix 3: Nisonger Child Behaviour Rating Form 


















THE NISONGER CHILD BEHAVIOR RATING FORM 
PARENT VERSION I 
Child's Name: ______________ _ Child's Date of Birth: __ -'-_-1-__ 
month day year 
Rater's Name: _____________ _ ~of~: ____ L_~L__ 
month day year 
Relation of Rater to Child: • parent [I] • other [9): _______________ _ 
(please specify) 
I. Please describe any special circumstances or mediating filcton; that may have affected the child's behavior in the 
recent past (the last month or two) or prevented you from making complete ratings. 
II. POSITIVE SOCIAL. Please describe the child's behavior as it was at home over the last month. 
Not Somewhat or Very or Completely or 
IN TIlE LAST MONfH. THIS CHU...O HAS: True Sometimes Often True Always True 
[0] True [2) [3] 
[I) 
I. Accepted redirection 
2. Expressed ideas clearly 
3. Followed rules 
4. Initiated positive interactions 
5. Participated in group activities 
6. Resisted provocation, was tolerant 
7. Shared with or he)ped othen; 
8. Stayed on task 
9. Was cheerful or happy 


















Nisonger CBRF: Parent 
Ill. PROBLEM BEllA VIOR. For each item that describes the child's behavior as it was over the last month, circle 
the: 
0 .... if the behavior did not occur or was not a problem 
I .... ifthe behavior occurred occasionally or was a mild problem 
2 .... if the behavior occurred quite often or was a moderate problem 
3 .... if the behavior occurred a lot or was a severe problem 
For each problem that occurred, circle only the score that best describes the behavior. 
PLEASE DO NOT SKIP ANY QUESTIONS . IF YOU DO NOT KNOW THE ANSWER OR HAVE NOT HAD A CHANCE TO 
OBSERVE THE C HILD FOR A GIVEN 11M~ CIRCLE TIlE ZERO. 
1. Apathetic or unmotivated . 
2 Argues with parents, teachers, or 
other adults 
3. Clings to adults,too dependent 
4. Cruelty or meanness to others 
5. Cry ing, tearful episodes ...... . 
6. Hits or slaps own head, neck, hands, 





or other body parts ....................... 0 
7. Defiant, challenges adult authority .0 
8. Knowingly destroys property 0 
9. Difficulty concentrating 
10. Disobedient ............... . 
11. Rocks body or head back and forth 
.0 
o 
repetitively . . . .. .. ... .. . . . . . .. 0 
12 Doesn't fee l guilty after misbehav ing ... 0 
13. Easi ly distracted ....... 0 
14. Easi ly frustrated.. .. . ... .. . .. .. .. . ..0 
15. Overly sensitive; feelings easily hurt ........ 0 
16. Exaggerates abilities or achievements ....... 0 
17. Explosive, easily angered. ........... ..0 
18. Has rituals such as head rolling or 
floor pacing. 
19. Fai ls to fini sh things he/she starts 
20. Feelings easily hurt ...... . 
21. Feels others are against himlher 
22. Harms self by scratching ski n or 
pulling hair ....... . 
23. Feels worthless or inferior 
24. Fidgets, wiggles, or squirms 
25. Shy around others; bashful ....... • ... 
26. Gets in phys ical fights ......... . 
27. lrritable .... 











or objects (such as pieces of string) . . . . . . 0 
29. Isolates self from others .. 0 
30. Lying or cheating. . . .. 0 
31. Nervous or tense . 0 
32 Gouges self, puts things in ears, nose, 
etc., o r eats inedible things. .0 


































34. Overly anxious to please others 
35. Overly excited, exuberant .. 
36. Physically attacks people ............ . 
... . . 0 
... 0 
.0 
... 0 37. Refuses to talk . . ......... . 
38. Repeats the same sound, word, or 
phrase over and over . 
39. Restless, high energy level 
40. Runs away &om adults, teachers, or 
other authority fi gures .......... . 
41. Says no one likes him/ber . 
42. Secretive, keeps things to self ... 
43. Repeatedly bites self hard enough to 
leave tooth marks or break skin 
44. Self·consc ious or easily embarrassed 
Shifts rapidly &om topic to topic 45. 








when talking .. . 
Short attention span ... 






Steals.. . ............ . 
Odd repetitive behaviors (e.g., stares, 




50. Stubborn, has to do things own way ........ 0 
51. Sudden changes in mood 0 
52. Sulks, is silent and moody ......... . .. 0 
53. Physically harms or hurts sclfon 
purpose. . .. .. . .. .. .. .. . .. 0 
54. Talks back to teacher, parents, or 
other adu lts. .. ... .. ... .. .. . ........... 0 






Threatens people. . . . .......... . 
Threatens to harm self. 
Engages in meaningless, repetitive 
body movements. . .......... . 
60. Too fearful or anxious ..... . 
61. Underactive, slow ... 
62. Unhappy or sad 
63. Violales rules 
64. Withdrawn, uninvolved with others. 
Worry ing. 
.0 









66. Argues with other children or peers .... 
.... . 0 
... 0 
PAGE 2 
















































5.4. Appendix 4: Nisonger Child Behaviour Rating Form 


















DIE NISONGER KIND GEDRAGSVRAEL YS 
OVER SE UITLEG 
Naam van kind: ... ......................................... . Geboortedatum van kind : ........ .1 .......... .1 .. ....... . 
Dag Maand Jaar 
Naam van die persoon wat die vraelys voltooi : Datum van evaluering: ... .. .1 ..... ..... .1 
Dag Maand '''' 
Verwantskap tussen eva lueerder en kind: 0 ouer [I] 0 aoder [9]: ..... 
(Spesifisccr asseblicf) 
I. 8eskryf asseblief enige spesiale omstandighede of indirekte [aktore wat die kind se gedrag mag 
betovloed het in die onlangse verlede (die afgeJope maand of twee), of wat u mag verhoed om 
volledige evaluerings te maak 
II. SOSlALE VERW ANTSKAPPE. Beskryf asseblief die kind se gedrag soos dit by die hui s was oor 
die afgelope 4 weke. 
Nie letwat of Baie or Hceltemalor 
Waar nie Soms waar Dikwels Waar Allyd Waar 
HI ERDIE KIND HET, GEDURENDE 
DIE AFGELOPE 4 WEKE: [0) [I) [2) [3[ 
I. Nuwe instruksics aanvaar 0 0 0 0 
2. Idees duidelik uitgedruk 0 0 0 0 
3. Reels nagekom 0 0 0 0 
4. Positiewe interaksies aan die gang gesit 0 0 0 0 
5. Aan groepsaktiwiteite dcelgeneem 0 0 0 0 
6. Provokasie weerstaan, 
was verdraagsaam 0 0 0 0 
7. Met andere gedee l of andere gchclp 0 0 0 0 
8. Met take volgehou 0 0 0 0 
9. Was opgeruimd of gclukkig 0 0 0 0 


















III. PROBLEEMGEDRAG. Vir e lke item wat die kind se gedrag beskryf soos dit oor die afgelope 4 
weke was, omkring die: 
0 .... indien die gedrag Die voorgekom het oie of Die 'n probleem was oie 
I .... indien die gedrag soms voorgekom het of'n geringe probleem was 
2 .... indien die gedrag beel dikwels voorgekom het of '0 matige problcem 
was 
3 .... indien die gedrag baie voorgekom het of '0 erostige probleem was 
Vir e Lke problccm wat voorgekom het, omkring slegs die telling wat die gedrag die beste beskryf. 
MOET ASSEBLIEF NIE EN IGE VRAE OORSLAAN NIE. lNOlEN U NlE DIE ANTWOORD KEN, OF 
NIE KANS GEHAD H-ET OM OlE KIND GEDUURENDE 'N BEPAALDE TYD WAAR TE NEEM NIE, 




Onbelangstellend of ongemotiveerd .............. . ..................... ............... 0 
Stry met ouers, onderwysers, of ander volwassenes .... . .............................. 0 
Kleef aan vo lwassenes, te afhankJik ........... ...................................... . ...... 0 
4. Wreedheid of gemeenheid teenoor andere...... ........................... . ....... 0 
5. Huilerig, tranerige episodes .... . ... ................. ....................................... .. .. ... 0 
6. Slaan of klap eie kop, nek. hande, of aDder ligga msdele ... . ............ ....... 0 
7. Uitdagend, daag volwasse gesag uit .................................................................. 0 
8. Vemietig eiendom bewustelik ..................................................... .. .................... 0 
9. Konsentreer met moeite ..................................... ... ............... ........................... 0 
I O. Ongehoorsaam............................................................. . ................................ 0 
I I . Wieg liggaam of kop herhaaldelik heen en weer ............. ........ ........................ 0 
12. Voel nie sku ldig na wangedrag nie ..................................................... ...... ........ 0 
13. Makl;k afgele; ................................................ . ............................................ 0 
14. Maklik gefrustreerd .............................................. .......... ... ..... ............... ... ..... .. .. 0 
IS. Oorsensitief; gevoelens maklik seer gemaak ................................................... 0 
16. Oordryf vermoens of prestasies .......................................... . .... ... .. .... .... 0 
17. Plofbaar, word makJik kwaad gemaak ........................................... .................. 0 
18. Het rituele soos kop rol of slap die vleer op en af ............ . .... ...... .. ............. 0 
19. Kan nie dinge afhandel wat hy/sy begin het nie .............................. ... .... ......... 0 
20. Gevoelens maklik seer gemaak .......... ... ....................... . ........... 0 
21. Voel dat andere teen homlhaar is ........... ...... ....................... . .. . 0 
22. Beseer homselflhaarself deur vel te krap of hare te trek ..... .. ......... ... ... ............ 0 
23. Voel waardeloosofminderwaardig ................... ........ . .......................... 0 
24. Vroetel, wikkel of skommel ............................... ..................... ............... .. .... .. 0 
25. Skaam tusseo andere, selfbewus ......................... . ................ ....................... 0 
26 . Raak betrokke in fi s ieke gevegte.................. ......... .................. . 0 
27. Prikkelbaar ..................................................... ....................... .... ... .... .. ..... ........ 0 
28. Klap ofwaai hande, vingers of klein dinge herhaaldelik ................................. 0 















































30. Lieg of verne uk ................................................ ...... ............................. ............ .. 0 2 3 
31. Senuwecagtig of gespanne ................................................ .... ........ ......... ........... 0 2 3 
32. Steek homselflhaarself, plaas dinge in ore, neus, ens., of eet oneetbare dinge. 0 2 3 
33. Ooraktief, sit nie stil nie.......................................................... .. .......... 0 2 3 
34. Oorangstig om mense genoee te verskaf.... .......... . ..................... .......... ... 0 2 3 
35. Ooropgewonde, uitbundig ........ .......................... .............................................. 0 2 3 
36. Val mense fi siek aan ....... ..................... . ......... ..... ..... ..... ........................ 0 2 3 
37. Weier om te praat ............................................................................................ 0 2 3 
38. Herhaal dieselfde klank, woord, of sinsnede oor en oar .............. . ... 0 2 3 
39. Rusteloos, hoe energiev lak ............................................................................... 0 2 3 
40. Hardloop van volwassenes, onderwysers, of ander gesagsfigure afweg .......... 0 2 3 
41. Se dat niemand van homlhaar hou nie ........................ ................. .. ............ 0 2 3 
42. Geheimsinnig, hou dinge vir homselflhaarself ............ ..... ............................... 0 2 3 
43. Byt homselflhaarselfherhaaldelik hard genoeg om tandmerke 
te los of om die vel slulckend te byt .................................................................. 0 2 3 
44. Selfbewus of word makJik skaam .................................................... .............. 0 2 3 
45. Skuifvinnig van onderwerp tot onderwerp terwyl hy/sy praaL ..................... .. 0 2 3 
46. Gee aandag vir net ' n kort tyd ............................ ............................................ ... 0 2 3 
47. Skaam ofvreesagtige gedrag ............... ...... ....................................................... 0 2 3 
48. Steel ........................................... ........................... .............................. .. .. 0 2 3 
49. Eienaardige herhalende gedrag (bv. Staar, gryns, rigiede houding) ................. 0 2 3 
50. Hardkoppig. moet dinge op eie manier doen . . ................................. 0 2 3 
51. Skielike verandering in bui .................. .. ........ ................... ............. . ......... 0 2 3 
52. Nukkerig, is sti l en buierig .................................................. .. .... ................ 0 2 3 
53. Skaad ofbeseer se lf fisiek opsetlik .................................................................. 0 2 3 
54. Praat terug teen onderwyser, ouers of ander volwassenes . ................ .............. 0 2 3 
55. Praat te vee) ofte hard............................................. .. ........ .. ...................... 0 2 3 
56. Woedebuie........................................................... . ....... .............................. 0 2 3 
57. Dreig rnense........... ........ .. .................. .. ...................................................... 0 2 3 
58. Dreig om selfte beseer.......... ................................................ .. ............... 0 2 3 
59. Betrokke in doeliose, herhalende liggaamsbewegings ...................................... 0 2 3 
60. Tebangofangstig ............................................................................................. 0 2 3 
6). Onderaktief, stadig ............................................. ............................. ..... .. .......... . 0 2 3 
62. Ongelukkig of treurig .... ....................... ... . .. ............ 0 2 3 
63. Oortree reels ..... ................................................................ ...... ........................ 0 2 3 
64. Teruggetrokke, onbetrokke by andere ............... .. .......................... 0 2 3 
65. Bekommerd ... .............................. .... ...... .. ..... ... .. .......... ........ 0 2 3 
66. Stry met ander kinders ......................... ...... ..................................................... . 0 2 3 
































Prevalence and Patterns of Medication Use in Children and Adolescents with Autism 
Spectrum Disorders in the Western Cape Information Sheet 
Dear Parent/Guardian, 
Thank-you for participating in this survey of medication use. There have been several studies in the 
United States of America exploring the prevalence and patterns of medication use in the autistic 
spectrum disorder population. There have been no studies to date in the South African context. The 
aim of this study is to look at the prevalence and patterns of medication use in children and 
adolescents with autism spectrum disorders in the Western Cape. The study will also look at what 
variables affect medication use, such as age and behavioural problems. Medication includes those 
prescribed by a doctor as well as over the counter preparations, vitamins, supplements and special 
diets. The information gained in this study will help to inform prescribing practices as well as to 
guide further research into the field of autism.   
In order to be included in the study your child must: 
 Be between the ages of 3 and 18 years. 
 Be living in the Western Cape. 
 Have a formal diagnosis of an autism spectrum disorder made by a doctor or psychologist.  
Autistic spectrum disorders include Autistic Disorder, Asperger’s Disorder and Pervasive 
Developmental Disorder Not Otherwise Specified. 
 Be attending an educational placement. 
This survey consists of two parts. The first is a two page questionnaire that must be filled out by a 
parent or guardian. There are questions about demographics, medications used, other medical and 
psychiatric conditions and educational placement.  This questionnaire has been adapted with the 
permission from author Dr Michael Aman from that used in American studies. The second part is a 
two page checklist specially designed to identify problem behaviours in children with developmental 
disorders.  The check list must be completed by a parent or guardian.   
Please follow the instructions carefully when completing the questionnaire and check list. It should 
take roughly 30 minutes to complete both parts of the survey. If your child is attending Alpha or Vera 
schools, your child’s teacher can help you to complete the forms if there are any difficulties. If you 
have gained access to the survey through Autism Action, please email the investigators if you have 
any concerns regarding the survey (medicationsurvey@gmail.com). Please complete one survey per 
child. If you have received a survey through Alpha or Vera schools as well as through Autism Action, 
please complete and return the school survey only. Do not complete two surveys. 
The information you provide will remain confidential at all times.  Your child’s name will not be used 
when reporting the findings. No one outside of the investigators will be allowed access to the 
information you have provided. In any future presentations or publications your child’s name will 
not be used. On completion, the findings from the study will be presented to all interested parties. 
You will be able to access the findings. 
Your participation in this survey is entirely voluntary. Should you chose not to participate or to 















participate in this study, there will be no direct benefit to you; however the information we obtain 
from this study will give a better understanding of the use of medications and supplements in 
children with Autism Spectrum Disorders in the Western Cape. This is only a survey so there is 
nothing painful or dangerous about participation; however you will be asked questions about your 
child’s health and about money which may be very personal.  Some people may find it difficult to 
discuss these matters.  
Once you have read and understood this information sheet, please sign the consent form giving 
permission to use the information you have provided for the purpose of this study. If your child is 18 
years old and you feel they are able to understand this information sheet, please ask for their 
permission to use the information provided about them for the study. If they agree they must sign 
the assent form provided. 
Please return the completed forms including the signed consent form to the school in the 
confidential envelope provided. If you have accessed the survey through Autism Action please post 
the forms back to the investigators in the envelope provided.   
































Prevalence and Patterns of Medication Use in Children and Adolescents with 
Autism Spectrum Disorders in the Western Cape Consent Form 
 
I,__________________________________________ (full name), the parent/ guardian of 
______________________________________________(full name) give consent for the information 
I have given in the questionnaire and Nisonger Child Behaviour Rating Form to be used in the study 
on the prevalence and patterns of medication use in children and adolescents with autistic spectrum 
disorders in the Western Cape. 
I have read and understood the information sheet of this survey. I understand that my participation 
in this study is entirely voluntary and should I choose not to participate, I will not be prejudiced in 
any way. I understand that full confidentiality will be maintained at all times and that consent can be 
withdrawn at any time. 
 
Signed:___________________________ 
Date (Day, Month, Year:)_____________________________ 
Place:_____________________________ 
 
This study has been reviewed and approved by the University of Cape Town Research Ethics 
Committee. If you have any questions about this study contact: 
Professor Marc Blockman  (Head of Faculty of Health Sciences Research Ethics Committee) 
Tel: 021 406 6338  
e-mail: marc.blockman@uct.uct.ac.za 
Dr Kerry-Ann Louw (Investigator) 
Tel : 021 685 4103 
































Prevalence and Patterns of Medication Use in Children and Adolescents with 
Autism Spectrum Disorders in the Western Cape Assent Form for Children 
Aged 18 years 
 
I,__________________________________________ (full name), give assent for the information 
given in the questionnaire and Nisonger Child Behaviour Rating Form to be used in the study on the 
prevalence and patterns of medication use in children and adolescents with autistic spectrum 
disorders in the Western Cape. 
I have read and understood the information sheet of this survey. I understand that my participation 
in this study is entirely voluntary and should I choose not to participate, I will not be prejudiced in 
any way. I understand that full confidentiality will be maintained at all times and that consent can be 
withdrawn at any time. 
 
Signed:___________________________ 
Date (Day, Month, Year:)_____________________________ 
Place:_____________________________ 
 
This study has been reviewed and approved by the University of Cape Town Research Ethics 
Committee. If you have any questions about this study contact: 
Professor Marc Blockman  (Head of Faculty of Health Sciences Research Ethics Committee) 
Tel: 021 406 6338  
e-mail: marc.blockman@uct.uct.ac.za 
Dr Kerry-Ann Louw (Investigator) 
Tel : 021 685 4103 




















Part B:Literature Review 
1. Objectives of the Literature Review 
A structured search was conducted to review the current literature on the prevalence of medication 
use amongst individuals with autism spectrum disorders (ASD), evidence for the use of psychotropic 
medication in individuals with ASD and evidence for the use of over the counter preparations, 
special diets, complementary and alternative medicines in individuals with ASD. 
2. Literature Search Strategy 
A search was conducted in PubMed using the following key terms: “autism”, “autism spectrum 
disorders”, “treatment”, “medication”, “complementary and alternative medicines”. The search was 
confined to literature in English. Human studies including children and adults were included. All time 
periods were searched. The earliest relevant paper identified was published in 1988. Studies were 
also identified using the reference lists of the papers generated from the original search. 
3. Summary of Literature 
3.1 Introduction 
The pervasive developmental disorders (PDD) are a group of neurobiological conditions, evident in 
the first few years of life, that follow a chronic course and are characterised by pervasive dysfunction 
in three core domains: reciprocal social interaction, communication and stereotyped behaviours 
(American Psychiatric Association, 2000). The DSM-IV (American Psychiatric Association, 2000) 
defines five PDD: Autistic Disorder, Rett’s Disorder, Childhood Disintegrative Disorder, Asperger’s 
Disorder and Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS). The Autism 















conditions show marked clinical heterogeneity with changing symptomatology relating to 
developmental stage (Seltzer, et al., 2003). 
The prevalence rates of Autistic Disorder vary markedly between epidemiological studies. According 
to the DSM IV, the mean prevalence rate is 5 cases per 10 000 with a range of 2 to 20 cases per 
10 000 individuals (American Psychiatric Association, 2000). Although evidence is lacking, PDD-NOS 
and Asperger’s Disorder appear to be more common (Bernet, et al., 1999). More recent United 
States of American estimates predict that 3 to 6 out of every 1000 children will have autism 
(National Institute of Health, 2009). These figures were concordant with data from studies from 
multiple sites and using varying methodologies (Geschwind, 2009). A 2009 review stated prevalence 
rates for ASD between 1 per 150 and 1 per 200 individuals and rates of 1 per 500 for the diagnosis of 
strictly defined autism (Geschwind, 2009). The apparent rise in prevalence remains a controversial 
issue and may be related to improved identification, and not a true rise, in incidence (Gurney, et al., 
2003). According to the statistics of Autism Western Cape, 1 in 86 South African children under the 
age of 6 is affected by autism and 10 children per week are being diagnosed at the Red Cross, 
Tygerberg and Lentegeur Psychiatric Hospitals (Autism Western Cape, 2009). These statistics have 
not been scientifically validated and may be an over estimate  
There is no cure for autism, but behavioural and pharmacological interventions are aimed at 
reducing core symptoms, managing other problem behaviours and treating psychiatric 
comorbidities. This allows for improved level of functioning and quality of life (Deokar, et al., 2008). 
Dysfunctional behaviours interfere with educational and rehabilitation interventions and can cause 
significant distress (Bernet, et al., 1999). Early identification of ASD and the implementation of 
sustained, appropriate educational and behavioural interventions improves long term clinical 
outcomes (Bernet, et al., 1999) (Tsai, 1999). 
Despite the implementation of educational and behavioural interventions, many individuals remain 















al., 2001). To date, risperidone is the only medication approved by the U.S Food and Drug 
Administration (FDA)for the treatment of problem behaviours, specifically irritability, aggression and 
self-injury, in children with autism (Food and Drug Administration, 2006). Psychotropic medications 
from all classes are currently in use including antidepressants, mood stabilizers, antipsychotics, 
antihypertensives and stimulants. Alternative and more easily obtainable over the counter (OTC) 
treatments such as megadose vitamins, herbal remedies and specialized diets are also used. There is 
minimal data about the long term safety of any of these agents (McCracken, 2005). 
3.2 Prevalence of medication use in ASD 
Medication surveys in the field of intellectual disability exposed elevated prescribing rates and 
served to guide changes in prescribing practices in the United States of America (Aman, et al., 2003). 
These studies did not specifically address ASD.  
There have been several scientific prevalence studies since 1995 which show that the ASD 
population is highly medicated, and is becoming increasingly medicated (Aman, et al., 1995) (Martin, 
et al., 1999) (Langworthy-Lam, et al., 2002) (Aman, et al., 2003) (Witwer, et al., 2005) (Aman, et al., 
2005) (Oswald, et al., 2007) (Gurney, et al., 2006) (Mandell, et al., 2008) (Esbensen, et al., 2009) 
(Rosenberg, et al., 2010). This body of epidemiological data is growing in parallel with systematic 
reviews into evidence supporting prescribing practices in ASD. These reviews reveal an urgent need 
for placebo-controlled trials of commonly prescribed medications (Tsai, 1999) (Posey, et al., 2001) 
(King, 2000) (Bodfish, 2004) (Palermo, et al., 2004) (Kwok, 2003) (Findling, 2005) (Leskovec, et al., 
2008) (Mc Dougle, et al., 2008) (Parikh, et al., 2008) (Siegel, et al., 2011) (McPheetters, et al., 2011) 
(Huffman, et al., 2011) (Warren, et al., 2011). The number of randomized controlled trials targeting 
the ASD population has increased over the last decade (Siegel, et al., 2011). 
Most available data on the prevalence of medication use in ASD comes from the United States of 















This was an informal survey completed by approximately 4000 parents of autistic children. The 
questionnaire included parental efficacy ratings. Thioridazine was the most commonly used drug 
(n=724), but high dose vitamin B6 and magnesium received the highest ratings for behavioural 
improvement.  
The first scientific study was a point prevalence survey conducted in the Autism Society of North 
Carolina in 1992 and 1993 (Aman, et al., 1995). The questionnaire elicited demographic and 
medication use information, specific data related to epilepsy, as well as parent satisfaction with 
treatment. Of the 838 respondents aged 1 to 82, 33.8% of the sample were taking some 
psychotropic drug or vitamin for autism or associated behavioural or psychiatric problems. If all 
agents, including vitamins, antiepileptics and other physical treatments were included, over 50% of 
the population were medicated. Neuroleptics were the most prevalent group (12.2%) with greater 
use of thioridazine than haloperidol. The next most commonly used drugs in order were: 
psychostimulants (6.6%), anxiolytics (6.3%), antidepresants (6.1%), antihypertensives (4.4%) and 
mood stabilizers (3.9%). Antiepileptic medications were considered as mood stabilizers in the 
absence of comorbid epilepsy. Of the sample, 19.2% were taking vitamins and 13.2% 
anticonvulsants.  Age and type of housing (a proxy variable reflecting difficulty in management) were 
found to be independent predictors of psychotropic medication use. 
A further two large point prevalence studies of medication use in individuals with ASD have since 
been conducted in questionnaire form (Aman, et al., 2003) (Langworthy-Lam, et al., 2002). The 
second study was done in the Autism Society of Ohio in 1999 and the third in the Autism Society of 
Carolina in 2001 (NC2). The three studies were done by the same group utilizing the same 
questionnaire and were later compared to assess longitudinal trends and regional effects (Aman, et 
al., 2005). There were significant increases in medication use with time.  
In the second Northern Carolina study, of the 1538 respondents between the ages 3 and 56, 45.7% 















increased to 53.1% with the inclusion of vitamins and antiepileptics. Antidepressants were the most 
commonly used psychotropic medication (21.7% of the sample), followed by antipsychotics (16.8%) 
and stimulants (13.9%). The longitudinal trend was a very large increase in antidepressant utilization 
with significant increases also occuring in antipsychotic, psychostimulant and anitihypertensive 
utilization. Changing patterns were thought to reflect increased physician prescribing of the newer 
selective serotonin reuptake inhibitors (SSRIs) and atypical antipsychotics. The first Carolina study 
had been completed before the introduction of these agents. These medications have greater 
perceived safety as well as a growing body of evidence to support their use (Mc Dougle, et al., 2008) 
(Leskovec, et al., 2008). In keeping with previous findings, greater age and greater severity of autism 
and intellectual disablility predicted psychotropic medication use. Interestingly, younger autistic 
individuals had increased use of autism supplements; possibly because parents of younger indivduals 
seek out more “natural” remedies.  
The Ohio study survey included 417 respondents aged 2 to 46 and findings were consistent with the 
second Northern Carolina study (Aman, et al., 2003). This went against the authors’ original 
hypothesis that there would be less medication use in Northern Carolina because of greater access 
to psychoeducational services.There was significantly greater use of supplements for autism in the 
Ohio group. There were strong demographic variable correlates between all three studies, with 
greater age and level of disability and more restrictive placement being associated with increased 
medication use. 
Psychotropic medication has been investigated in a specific subgroup of individuals with higher 
functioning autism and Asperger’s disorder (Martin, et al., 1999). In addition to demographic and 
medication information, data collection included developmental, behavioural and educational 
inventories such as the Autism Behaviour Checklist (ABC). The sample was drawn from children, 
adolescents and adults attending the Yale Child Study Center’s Project on Social Learning Disabilites 















taking psychotropic medications with 29.3% taking more than one medication. These findings reflect 
similar rates to those of the general ASD population. Antidepressants were the most commonly used 
agents (32.1%) followed by stimulants (20.2%) and antipsychotics (16.5%). The high rate of SSRI use 
was again attributed to presciption practices related to limited side effect profile and the perception 
of the “benign” nature of these medications. An added dimension to this study was the inclusion of 
prescribing practices. Medications had been prescribed by general psychiatrists in 58.3% of the 
sample, child psychiatrists in 26.7% and by neurologists and paediatricians in 10%. There was 
marked clinical heterogeneity within the sample, with many symptoms that were unrelated to the 
core features of autism being treated pharmacologically. Of note were the high rates of depression 
and anxiety symptoms. 
The above studies are all point prevalence studies which are reliable in extracting information about 
current medication use, but limited in reflecting the use of medications that are not constantly 
administered. This aspect was addressed in a study by Witwer and Lecavelier where information was 
obtained from 353 participants regarding 1 year rates and patterns of medication use (Witwer, et al., 
2005). The aim of the study was to focus on the younger population with the inclusion criterion of 
age between 3 and 21 years. Parents also completed the Nisonger Child Behaviour Rating Form to 
identify problem behaviours and the Scale of Independent Behaviour-Revised, which is a 
standardized measure of adaptive behaviour. The one year rates of medication use were found to be 
similar to previous point-prevalence studies, supporting the reliability of point prevalence data. Of 
the subjects, 46.7% had taken at least one psychotropic medication in 1 year, 17.3% some type of 
vitamin and 15.5% were on a specialized diet. The most prevalent medications were 
psychostimulants (24%), followed by antidepressants (21.2%), antipsychotics (19.5%), alpha agonists 
(10.9%) and mood stabilizers (4.2%). Compared to previous studies, a higher percentage of children 
and adolescents were taking psychostimulants and antipsychotics. Differences in neuroleptics were 
accounted for by the increasing trend of atypical antipsychotic prescribing, due to mounting 















contribute to the higher percentage of respondents having used antipsychotics, as children may 
have been given brief trials of antipsychotics over the year. Stimulant use was thought to be higher 
because of the nature of the age demographic of the sample. Greater age, lower adaptive skills and 
social competence and higher levels of problem behaviour were associated with greater medication 
use. 
The findings of these large questionnaire based surveys are supported by evidence from cross-
sectional telephone (Gurney, et al., 2006) and internet surveys (The Interactive Autism Network, 
2008) (Green, et al., 2006). 
A limitation of surveys that utilise parental reporting is that they rely on parent recollections. Several 
studies have addressed this issue by altering methodological design to draw on information from 
various sources of medical records and databases (Oswald, et al., 2007) (Mandell, et al., 2008) 
(Shimabukuro, et al., 2008) (Rosenberg, et al., 2010). With access to large databases and without the 
limitation of non-response, sample sizes tend to be much larger. The findings from these studies are 
discussed below. 
Oswald and others collected data from the 2002 commercial claims and encounters databases of a 
healthcare information company (Oswald, et al., 2007). Their sample included all individuals under 
the age of 21 and information was reviewed regarding demographics, medication use as well as 
inpatient admissions and outpatient visits. Of the 2390 individuals with ASD, 83% had at least one 
drug claim in the last year from 125 medication classes. Of the sample, 57% received psychotropic or 
anticonvulsant medications. This finding is in keeping with point prevalence studies and supports the 
reliablility of the parent survey data. The most common class of psychotropic medication used was 
antidepressants (32.1%) followed by stimulants (26.9%), antipsychotics (23.5%), anticonvulsants 
(15.2%), hypotensive agents (11.9%), hypnotics (5.8%) and benzodiazepines (4.2%). Antidepressants, 
antipsychotics and anticonvulsants showed increasing use with age. A limitation was that this study 















methodology, is that data reflects what prescriptions were filled, and not whether medications were 
actually taken.  
Mandell and others conducted a cross-sectional study of 60641 children with ASD using Medicaid 
claims from 2001 to determine patterns of psychotropic medication use (Mandell, et al., 2008). 
Medicaid is the United States Health care programme for individuals with low incomes and 
resources and it includes individuals with disabilities (Wikipedia, 2009). The study collected 
demographic data, information regarding psychotropic medication use and data on County and State 
characteristics. Of the sample, 56% used at least 1 psychotropic medication during 2001, with 20% of 
these using more than 3 concurrently. Neuroleptics were the most commo  (31%), followed by 
antidepressants (25%), stimulants (22%), mood stabilizers (21%), anxiolytics (12%) and sedatives 
(3%). Older children were more likely to use medication. Children in foster care had the highest rates 
of use of psychotropic medications. Children who had an inpatient stay were more likely to use 
medication. Differences were found between the ASD, with 61% of children with Asperger’s disorder 
and PDD-NOS taking psychotropic medications and 53% of children with an Autistic disorder 
diagnosis taking psychotropic medications.The proportions of individuals using medications in this 
study could be higher than community based samples, because children accessing Medicaid may be 
more severely affected by autism. 
Rosenberg and others examined psychotropic medication use among 5 181 children aged 18 years 
and younger with ASD enrolled in a national web-based registry (Rosenberg, et al., 2010). The 
Interactive Autism Network is an internet based research database that continually collects data 
from families of children with ASD. Of the total sample, 35% were using at least one psychotropic 
medication. The most commonly reported psychotropics were stimulants (15.4%), neuroleptics 
(15%) and antidepressants (13.6%). Patients insured by Medicaid were more likely to use 















Psychotropic use was more likely in children of older age, children with intellectual disability or 
psychiatric comorbidity. 
A study by Shimabukuro and others analysed medical expenditures data collected from a large USA 
market research databases (Shimabukuro, et al., 2008). On average, medical expenditures for 
children and adolescents with ASD were 4.1 to 6.2 times greater than for those without ASD. In 
keeping with the above studies psychoactive medication use was positively associated with 
increasing age. 
To date, there has been only one longitudinal study of medication use among individuals with ASD 
(Esbensen, et al., 2009). Esbensen and others examined 286 adolescents (10 years or older) and 
adults over a 4.5 year period. Their findings confirmed the high prevalence rates of medication use 
and the increasing use of medication over time. Initially 70% of individuals were taking psychotropic 
or non psychotropic medications. This increased to 81%, 4.5 years later. At the beginning of the 
study, 57% took at least one psychotropic medication and 37% took at least one non-psychotropic 
medication. For both types of medication, the number of medications and the proportion of 
individuals taking medications increased with time. Of the nonmedicated individuals in the sample, 
30% began taking medication during the study timeframe. Higher rates of medication use than those 
presented in previous studies can be related to the older age of the sample. Older age has already 
been shown to predict increasing medication use (Aman, et al., 2005). Adolescents have an 
increased risk of developing seizure disorder and psychiatric comorbidity (American Psychiatric 
Association, 2000) which could explain greater medication use with age. The longitudinal increases 
in medication use could reflect changes in prescribing practices as discussed above. The authors 
conclude that more people with ASD are taking medications and that more medications are taken 
over time. Individuals who are medicated are likely to stay this way, the pattern being more 















The above studies use various methodologies to explore the prevalence and patterns of 
psychotropic use among idviduals with ASD. Despite the various methodologies, all studies report 
similar findings. Findings from the longitudinal study and studies using large databases show similar 
data to those of point prevalence survey studies. This population is highly medicated with increasing 
use of medications reflecting changes in prescibing patterns.  

















Table summarising the frequency of use of specific drugs reported in the studies discussed above. 
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There have also been studies that have focused exclusively on the prevalence of use of 
complementary and alternative medicines in the ASD population. The definition of complementary 
and alternative medical therapy differs in different texts and can include a variety of therapies such 
as food supplements, modified diet, herbal remedies, vitamins and minerals, over the counter 
medications, as well as mind-body techniques such as meditation and accupuncture. United States 
of American national estimates report that approximately 2% of all children use complementary and 
alternative medicines (Davis, et al., 2003). These estimates are higher for children with disability or 
chronic illness (Hanson, et al., 2007). There is a vast amount of literature promoting these therapies 
in ASD, however there have been few published studies that focus on the supporting evidence base 
and the prevalence of these therapies. The findings from two recent prevalence studies will be 
discussed below. 
A 2006 study by Hansen and others found that 74% of 112 families surveyed used complementary or 
alternative medicines for their child with ASD (Hanson, et al., 2007). This group defined 
complementary and alternative medicines as modified diet, food supplements, herbal remedies, 
vitamins, minerals, biofeedback, chiropractic and osteopathic manipulation, guided imagery, healer 
touching, massage, meditation, prayer and special exercises. Biologically based therapies were used 
in 54% of the sample and these included modified diet (38%), vitamins/minerals (30%), food 
supplements (23%), herbal remedies (11%) and secretin (8%). Several reasons for parents seeking 
out alternative therapies are listed in the discussion and included the lack of a single treatment for 
the core symptoms for autism, poor access to treatment, the perception that such treatments are 
more “natural”and concerns around the dangers of prescription medications.  
A 2007 study by Wong and Smith compared the use of complementary and alternative medical 
therapies in a group of children with ASD (n=50) with a control group (n=50) (Wong, et al., 2006). 
Parents were asked about alternative medical systems (aromatherapy, homeopathic remedies, 















mineral and vitamin supplements, vitamin supplements), manipulative and body based therapies 
(body based relaxation therapies, chiropractic, massage, sensory integration, therapeutic horseback 
riding) and mind-body and psychological therapies (music therapy, spiritual healing). More than half 
of the parents in the ASD group reported using or had used at least one of these therapies for their 
child (52%) compared to only 28% of the control group. The majority had used one or two therapies.  
To our knowledge, there is no published evidence regarding the prevalence and pattern of 
psychotropic or over the counter medication use in children with ASD within the South African or 
African context. 
3.3 Psychotropic medications in ASD 
Despite the growing prevelance of medication use in this population, the evidence base to support 
the prescribing of medications remains small. The pathogenesis of autism is not fully understood and 
as yet there is no cure (Kwok, 2003). First line interventions include behavioural and cognitive 
strategies. These include parental counselling, behaviour modification, special education techniques, 
sensory integration training, speech therapy, social skills training and other communication and 
social interventions (Tsai, 1999) (Bodfish, 2004). Applied behaviour analysis (ABA) has a large body of 
supportive evidence (Geschwind, 2009). These interventions are thought to be most powerful when 
initiated early on. A recent systematic review of interventions for children ages 2 to 12 wth ASD was 
conducted by the Vanderbilt Evidence-based Practice Center (Warren, et al., 2011). The reviewers 
found that evidence supported early intensive behavioural and developmental interventions. 
However, lack of consistent data limited understanding of whether these interventions were linked 
to clinically meaningful changes in functioning. 
Distressing and abberant behaviours interfere with the implementation of behavioural and 
educational interventions. Medication targets these distressing and abberant behaviours. This 















response to behavioural and cognitive strategies (Tsai, 1999) (Kwok, 2003). Effective 
pharmacological treatments are needed to assist children to achieve their full potential in the least 
restrictive environment (Siegel, et al., 2011). 
While the core features of autism include impairments in social interactions, impaired 
communication skills and stereotyped patterns of behaviour, interests and activities; other 
behaviour symptoms are common. According to Tsai, about 60% have poor attention and 
concentration; 40% are hyperactive; 43%-88% exhibit morbid or unusual preoccupation; 37% have 
obsessive phenomena; 16%-85% show compulsions or rituals; 50%-89% demontrate stereotyped 
utterances; 70% exhibit stereotyped mannerisms; 17%-74% have anxiety or fears; 9%-44% show 
depressive mood, irritability, agitation and inappropriate affect; 11% have sleep problems; 24 %-43 
% have a history of self injury; and 8% have tics (Tsai, 1999). These behaviours, which were 
previously thought to be associated features of autism, are now considered to be features of 
coexisting neuropsychiatric conditions such as attention deficit hyperactivity disorder (ADHD), 
affective disorders, obsessive compulsive disorder and Tourette disorder (Tsai, 1999). These 
associated behavioural symptoms may be amenable to medical therapy. 
Psychiatric comorbidities are common in children with ASD with estimate prevalence rates between 
25%-70% (Geschwind, 2009). A population derived cohort study found high rates of psychiatric 
disorders and frequently multiple disorders in children with ASD (Simonoff, et al., 2008). Of the 112 
participants, 70% had one disorder and 41% had 2 or more disorders. The most common diagnosis 
was social anxiety disorder (29,2%), followed by ADHD (28,2%) and oppositional defiant disorder 
(28,1%). Clinical dysfunctions in other domains are also common in individuals with ASD. These 
include sensory abnormalities, developmental regression, motor signs such as hypotonia and 
apraxia, gross motor delay, sleep disturbance, and gastrointestinal disturbance (Geschwind, 2009). 















Studies show that neurochemical factors play a role in the pathogenesis of autism. These theories 
provide the rationale for psychopharmacological practices. Tsai summarized  neurochemical data in 
his 1999 review. Theories exploring the role of serotonin in autism include those of 
hyperserotonemia, decreased serotonin binding and decreased central serotonergic responsivity. 
Current evidence concerning the role of dopamine in autism is mixed, but dopamine agonists have 
been shown to worsen preexisting stereotypies, aggression and hyperactivity. The evidence 
regarding norepinephrine and epinephrine is also inconclusive with some studies showing lower 
levels in individuals with autism. Neuropeptide studies have shown abnormalities in autistic subjects 
and autistic behaviours resembling opiate-induced behaviours in animals and certain behaviours 
seen in adult oppiate addicts (Tsai, 1999). In a recent review, Parikh and others discussed the 
neurochemical underpinnings of aggressive and self injurious behaviours in individuals with autism 
(Parikh, et al., 2008). Several studies related to the dopaminergic and serotonergic systems as well as 
the noradrenergic and endogenous opioid systems are cited (Parikh, et al., 2008). 
There have been a number of reviews in the past decade concerning the evidence base supporting 
prescribing practices in individuals with autism. Medication studies differ widely in terms of study 
sample, sample size, research design, purpose of treatments and measures of response (Huffman, et 
al., 2011). There are several medications that have been identified as possibly being effective in 
treating autism, but additional clinical trials are much needed (Leskovec, et al., 2008). There have 
been four recent systematic reviews of medications used in children with ASD. These reviews used 
different study inclusion criteria, assessed different targets of treatment and used different methods 
of assessing the strength of the included studies. The findings of these three reviews will be 
discussed below. 
The 2011 review by McPheeters and others reviewed the evidence for antipsychotics, serotonin-
reuptake inhibitor and stimulant medications used for children younger than twelve with ASD 















experts involved in ASD care. Studies had to include at least 30 participants and have been published 
after the year 2000. Two investigators independently assessed the studies using a quality 
assessment form developed by the review team and experts in the field. The reviewers identified 18 
studies of medical interventions of which 10 were randomised controlled trials. The findings of this 
review are summarised as follows: 
Antipsychotics: There were 4 RCTs of risperidone identified, two of which targetted challenging 
behaviour as the primary outcome (McCracken, et al., 2002) (Shea, et al., 2004). The studies showed 
a moderate improvement in challenging and repetitive behaviours. All RCT studies and prospective 
case series reported significant adverse events especially weight gain, sedation and extra pyramidal 
effects. Two 8-week, industry funded RCTs of aripiprazole showed improvement in challenging and 
repetitive behaviours (Owen, et al., 2009) (Marcus, et al., 2009). The most commonly reported 
adverse events were weight gain, sedation and extra-pyramidal effects.  
Serotonin-Reuptake Inhibitors (SRI): A 12-week RCT of citalopram showed no significant difference 
betweeen groups (King, et al., 2009). Adverse events reported included activation symptoms and 
gastrointestinal effects. In a single cross over design RCT of fluoxetine versus placebo, subjects in the 
fluoxetine group showed greater changes in repetitive behaviours (Hollander, et al., 2005). The 
reviewers found the overall strength of evidence for the ability of serotonin reuptake inhibitor 
medications to reduce repetitive or challenging behaviours to be insufficient. 
Psychostimulants: In a large, double blind placebo control study by the Research Units on Paediatric 
Psychopharmacology (RUPP) methylphenidate was shown to have efficacy but with reduced 
effectiveness and a less satisfactory side effect profile (Research Units on Pediatric 
Psychopharmacology Autism Network, 2005). Adverse effects reported included appetite and sleep 
changes, anxiety, depression, headache and diarrhoea. The reviewers found the strength of 















The reviewers conclude that most of the medications currently being used to treat children with ASD 
lack sufficient evidence. Risperdone and aripiprazole were found to be the two best studied 
medications for ASDs. Both challenging and repetitive behaviours showed improvement in these 
trials. However their significant association with adverse effects limits their use. 
The 2011 systematic review of psychotropic medications in children with ASD by Siegel and Beaulieu 
included all typically prescribed psychotropic agents having undergone randomised controlled trial in 
participants 18 years old or younger (Siegel, et al., 2011). There was no date of publication exclusion 
criterion. The review was conducted using methodology developed by Reichow and colleagues to 
evaluate the quality of research in autism. The Evaluative Method for Determining Evidence Based 
Practice in Autism uses quality indicators to determine the strength of a study then assigning an 
evidence rating by combining the amount and quality of studies performed on an intervention 
(Reichow, et al., 2008). Thirty-three RCTs were included in the review. The results of the review are 
summarised below: 
Alpha-2 Agonists: Clonidine and guanfacine both had insuficient evidence to recommend their use. 
Antipsychotics: In keeping with the McPheeters et al review, riperidone was found to have 
established evidence for efficacy in the treatment of irritability and hyperactivity, and preliminary 
evidence for effficacy in reducing repetitive behaviours and stereotypy. The two industry funded 
trials of aripiprazole were found to have evidence for efficacy in reducing irritability, hyperactivity 
and stereotypy (Marcus, et al., 2009) (Owen, et al., 2009). Two older RCTs on haloperidol were 
reviewed (Anderson, et al., 1984) (Anderson, et al., 1989). Both studies received strong research 
ratings suggesting that there may be a role for haloperidol in cases of refractory negative 
behaviours. Risperidone was found to be superior to haloperidol in a head-to-head comparison 
(Miral, et al., 2008). However this study only obtained adequate research strength rating. Due to a 
weak research strength rating and the high frequency of weight gain, olanzapine was not 















Mood stabilisers: The evidence for divalproex sodium was mixed and found to be insufficient for use 
to treat irritability in children with ASD. Lamotrigine and levitiracetam had been studied in one RCT 
each with no evidence of an effect when compared to placebo (Belsito, et al., 2001) (Wasserman, et 
al., 2006). 
Norepinephrine reuptake inhibitors: Based on a small RCT there was preliminary evidence for the 
efficacy of atomoxetine for hyperactivity (Arnold, et al., 2006). 
Serotonin reuptake inhibitors: The citalopram RCT by King and others obtained a strong research 
rating but found no significant effects on repetitive behaviour (King, et al., 2009). The fluoxetine 
cross over RCT by Hollander and others obtained a weak research strength rating with positive but 
likely insignificant results (Hollander, et al., 2005). There was insufficient evidence to support the use 
of clomipramine. 
Stimulants: The reviewers identified three RCTs, including the RUPP study, investigating 
methylphenidate (Research Units on Pediatric Psychopharmacology Autism Network, 2005) 
(Handen, et al., 2000) (Quintana, et al., 1995). Overall the level of evidence for methylphenidate in 
the treatment of hyperactivity in children with ASD was promising. 
Miscellaneous agents: The reviewers found that there was insufficient evidence for amantadine, 
cyproheptadine and donepezil. Naltroxone studies had conflicting results. There was preliminary 
evidence for the use of pentoxifylline, a methylxanthine with immunologic and serotonergic effects, 
for the treatment of irritability and social withdrawal. 
The reviewers concluded that only a few psychotropic medication had strong enough research data 
to obtain a rating of “ Established Evidence”. Risperidone and aripirazole had established evidence 
for treatment of irritability and hyperactivity and aripiprazole also had established evidence for the 
treatment of stereotypy. Haloperidol had established evidence for the treatment of negative 















atomoxetine for the treatment of hyperactivity; riperidone for repetitive behaviour and stereotypy 
and pentoxyfilline in combination with riperidone for irritability and social withdrawal. The reviewers 
identified several limitations of pharmacotherapy trials in the ASD population including 
heterogeneity in the autism phenotype and the lack of accepted diagnostic tools to establish co-
ocurring psychopathology. 
The 2011 review of pharmacological treatments for ASD by Huffman and others included studies 
from 1994 to 2007 of individuals 0-22 years of age (Huffman, et al., 2011). There were 89 articles 
addressing pharamcological treatments identified. Reviewers used methodology in keeping with the 
Cochrane Collaboration for their literature review. Study quality assessment was based on domains 
used in the National Standards Project of the National Autism Center. Studies were allocated a score 
based on a Scientific Merit Rating Scale. This review included studies of complementary-alternative 
medicine (CAM) treatments which will be discussed below. Treatment response was organised by 
ASD symptoms, differentiating core and associated symptoms. Core symptoms were categorized as 
general; impaired social interaction; impaired communication and restricted, repetitive behaviour. 
Associated symptoms included maladaptive behaviour symptoms; which were further categorized 
into general, hyperactivity and aggression; and dysregulation symptoms which were divided into 
irritability, sleep problems, sensory abnormalities and gastrointestinal problems. Risperidone was 
found to be efficacious and safe for core symptoms, maladaptive behaviour, hyperactivity and 
irritability. Methylphenidate was effective in reducing symptoms of inattention and hyperactivity. 
All other medications included in this review were found to have marginal evidence only or to be 
ineffective. The reviewers concluded that many pharmacological treatments have minimal or no 
emperical data to support their use. Medications may show benefit in certain target areas but not 
others. 
The Vanderbilt Evidence-based Practice Center systematically reviewed studies on therapies for 















2011). This review included medications, complementary and alternative medicines (discussed 
below) and behavioural interventions. Study inclusion and exclusion criteria were developed in 
consultation with a technical expert panel. The authors used methods outlined by the Evidence-
based Pracice Center to assess the quality of individual studies. Of 159 studies included 13 were 
found to be good quality, 56 were fair and 90 were poor. A total of 42 medication studies were 
identified of which 27 were RCTs. The authors concluded that the antipsychotic drugs risperidone 
and aripiprazole are the best studied medications in ASD and that they demonstrated significant 
improvement in challenging behaviour. These behaviours included emotional distress, aggression, 
hyperactivity, and self injury. The authors note however that medication side effects are significant. 
Both risperidone and aripiprazole caused weight gain, sedation and extrapyramidal symptoms. The 
strength of evidence for SRIs and stimulants was found to be insufficient. No medical treatments 
demonstrated benefit for social or communication symptoms in ASD. 
3.4 Over the counter preparations, special diets, complementary and alternative medicines in ASD 
A range of special diets, dietary supplements, vitamins, minerals and complementary and alternative 
medicines have been used in ASD. These have very limited supporting data. The review by the 
Vanderbilt Evidence-based Practice Center found that there was insufficient evidence to assess 
supplements and other agents including omega 3 fatty acids (Warren, et al., 2011). The 2011 review 
by Huffman and others identified 26 articles addressing complementary and alternative medicines 
(Huffman, et al., 2011). There were inadequate number of studies to draw conclusions about the 
benefit of these agents in treating core or associated symptoms of ASD. A 2010 review of 
complementary and alternative medicines in autism identified several agents as being safe, but very 
few had evidence to support their efficacy (Atkins, et al., 2010). Melatonin was considered to be safe 
and effective in treating sleep difficulties. The following agents were identified as being safe but with 















fatty acids, methyl B12, folic acid, glutathione, dimethylglycine, gluten free diets, casein free diets. 
Secretin was considered safe but there was good evidence that it is not efficacious.  
3.5 Conclusion 
Autism spectrum disorders are a complex group of imprecisely described disorders with a wide 
range of clinical and behavioural manifestations. It is unlikely that any specific set of interventions 
would address all the clinical problems associated with these disorders. This adds to the difficulty in 
interpreting the literature which includes studies that may not be comparable. 
The key findings of this literature review include: 
 The autism spectrum disorder population is a highly medicated group. 
 There is limited data to support the prescribing of psychotropic medications in this 
population. 
 There is currently insufficient data to support the use of over the counter preparations, 
special diets or alternative and complementary medicines in this population. 
3.6 Limitations of the literature 
There is a vast literature around medication and OTC prescribing in the ASD population. However, 
there are marked inconsistencies when comparing the methodology between published studies. This 
makes it difficult to summarise and review the literature as a whole. Firstly, the definition and 
diagnosis of ASD conditions varies between studies. Authors use different diagnostic tools and it 
often unclear from the literature how diagnoses were made and how severity of autism has been 
determined. Studies also target different populations within the ASD community and again this 
brings into question comparisons made across studies. Some studies have looked at children only 
while other include all age groups. Secondly, medications are classed differently in studies. For 
example in some cases antiepileptics were seperated as mood stabilisers while in others they were 















studies as a single category while in others they were seperated according to their mechanism of 
action. The literature around over the counter and complementary medications is even more 
confusing with authors using different definitions and OTC classification systems. Thirdly, studies 
have used different methods of collecting data. There are large point prevalence surveys as well as 
large database studies. Survey information is limited by recall and reporting bias while database data 
may not reflect real life practice. There has only been one longitudinal study which is a large gap in 
this body of literature. Longitundinal studies provide valuable information reflecting changing 
prescribing practices as well as reflecting the changing symptomatology of these disorders as 
individuals age. Even though studies using different methologies have all shown that this group is 
highly medicated, the differing methodologies make comparisons difficult. There is a need for large, 
multicenter, coordinated research.  
The recent publication of medication systematic reviews provides valuable information about the 
evidence base supporting prescribing practices in the ASD population. The overwhelming conclusion 
is that evidence supporting prescribing practices is lacking. This is particularly evident in the CAM 
and OTC literature. The medication systematic review literature is problematic. Each review used 
different inclusion criteria, assessed different targets of treatment and used different methods of 
assessing the strength of the evidence. This makes the literature hard to compare and confusing to 
interpret. These differences may reflect the lack of standardised diagnostic methods and treatment 
outcome measures in the ASD population. In general these disorders include a broad range of clinical 
and behavioural symptoms whose underlying neurobiology remains poorly understood. This may 
explain the inconsistencies found in the literature. 
None of the studies explored the stigma surrounding medication use in this population or the 
reasons why parents or individuals choose to use certain medications. There are a many cultural 
factors that affect access to health care and adherance practices and this has not been addressed in 















The is limited research around ASD in the African and South African context. Differences in 
diagnosing and prescribing practices would make comparisons to international literature difficult. 
4. Need for Further Research 
To our knowledge, there is no evidence regarding the prevalence and pattern of medication use in 
children with ASD within the South African and African context. Our unique demographic and social 
environment may reflect patterns that are not in keeping with international trends. This knowledge 
is vital to inform clinical practice and guide future research. In the area of ASD particularly, there is 
persisting use of medications in the absence of an adequate evidence base. In a low resource setting 
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Objective: This study was conducted to investigate the prevalence and patterns of medication use 
amongst a sample of school going children and adolescents with autism spectrum disorders (ASD) in 
the Western Cape.  
Method: This was a descriptive, quantitative, analytic study. A survey questionnaire and the 
Nisonger Child Behaviour Rating Form (NCBRF) were utilized to collect relevant data from parents of 
children and adolescents recruited from two schools for children with ASD in Cape Town. 
Participants were also recruited from the Autism Action database.  
Results: A total of 24.6% of 65 children used psychotropic medications. Antipsychotics were the 
most commonly prescribed psychotropics followed by stimulants, antidepressants and mood 
stabilisers. Complementary and alternative medications were also commonly used with 40% of 
children using over the counter medications (OTC) and 15.4% being on a special diet for autism. 
Children of black or coloured ethnicity were less likely to use OTC medication than children in the 
white/asian ethnic group.  
Conclusions: In keeping with international studies this sample of children with ASD was a highly 
medicated group. The findings of this pilot study were limited by the sample size but it provides 
















The Autism Spectrum Disorders (ASD) are a group of neurobiological conditions characterised by 
pervasive dysfunction in three core domains: reciprocal interaction, communication and stereotyped 
behaviours (American Psychiatric Association 2000). The term ASD encompasses Autistic Disorder, 
Asperger’s Disorder and Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS). 
Prevalence rates of ASD vary between epidemiological studies. Approximately 6 out of every 1000 
children have an ASD diagnosis (Johnson and Myers 2007). There is no cure for autism. The goal of 
treatment is to optimise the child’s functioning by minimising core symptoms and treating other 
behavioural symptoms and psychiatric co-morbidities. There are several early, intensive behavioural 
and developmental interventions that demonstrate variable outcomes (Warren et al 2011a). 
Pharmacological treatments are aimed primarily at reducing distressing or disruptive behaviours to 
allow children to participate in cognitive and behavioural programmes (Kwok 2003). While reviews 
consistently conclude that there is a lack of evidence to support medication prescribing practices in 
the ASD population, prevalence studies show that this population remains highly medicated with 
both psychotropic and over the counter agents. 
There have been several large population based prevalence studies that show that the ASD 
population is highly medicated (Aman et al 1995, Aman, Lam and Collier-Crespin 2003, Langworthy-
Lam, Aman and Van Bourgondien 2002, Martin et al 1999, Witwer and Lecavalier 2005). These 
findings are supported by data from insurance claims and large database samples (Mandell et al 
2008, Oswald and Sonenklar 2007, Rosenberg et al 2010). Medications include psychotropics and 
over the counter (OTC), complementary and alternative medicines. The most commonly prescribed 
psychotropic medications in the ASD population include antipsychotics, antidepressants and 
stimulants with 30-60% of children with ASD taking at least one psychotropic medication (Aman et al 
1995, Langworthy-Lam et al 2002, Mandell et al 2008, Martin et al 1999, Oswald et al 2007, 















co-morbidity have been shown to predict psychotropic medication use (Aman et al 1995, 
Langworthy-Lam et al 2002, Mandell et al 2008, Oswald et al 2007, Rosenberg et al 2010). 
There has been a growing number of randomised control trials of psychotropic medications in the 
ASD population in the last decade. However, the evidence base supporting current prescribing 
practices remains poor. Recent reviews concluded that most of the psychotropic medications used 
to treat children with ASD lack sufficient evidence (Huffman et al 2011, McPheeters et al 2011, Siegel 
and Beaulieu 2011, Warren et al 2011b). Risperidone has been the best studied psychotropic and it 
is currently the only medication approved by the Food and Drug Administration for the treatment of 
problem behaviours in children with autism. Notably, risperidone does not influence the core 
features of ASD, but rather the associated behaviours.  
A range of special diets, dietary supplements, vitamins, minerals and other complementary or 
alternative medicines has been widely used in ASD (Akins, Angkustsiri and Hansen 2010, Hanson et al 
2007, Warren et al 2011b, Wong and Smith 2006). These agents may be used to such a great extent 
because there is no cure for autism and because no pharmacologic agent has been shown to be 
effective in managing the core symptoms of autism (Hyman and Levy 2000). These agents are also 
perceived as being safer than prescribed medications (Hanson et al 2007). 
The evidence for the efficacy of complementary and alternative medications in the ASD population 
also remains poor. The following agents have been identified as being safe but with unknown 
efficacy: vitamin C, mulivitamins, vitamin B6, magnesium, carnosine, carnitine, essential fatty acids, 
methyl B12, folic acid, glutathione, dimethylglycine, gluten free diets, casein free diets; and there is 
currently insufficient evidence to support their use (Akins et al 2010, Huffman et al 2011).  
To our knowledge there is no published evidence regarding the prevalence and patterns of 
medication use in a South African (or African) ASD population and whether this mirrors the use of 















populations would assist in disseminating accurate information to professionals and families, which 
in turn would promote the development of rational and evidence based approaches to the 
management of children with ASD in South Africa. 
Aims and objectives 
The aim of this study was to investigate the prevalence and patterns of medication use amongst a 
sample of school going children and adolescents with ASD in the Western Cape. The first objective of 
the study was to describe the prevalence of the use of psychotropic medications, OTC preparations 
and special diets as well as to explore the patterns of prescribing including the designation of the 
prescriber and the indication for use. The second objective was to determine the relationship 
between sample variables (age, ethnicity, income and child behaviours) and medication use. 
Methods 
This was a descriptive, quantitative, analytic study. 
Sample 
The sample was purposefully ascertained and was drawn from two schools for children and 
adolescents with ASD and the database of Autism Action South Africa. Inclusion criteria included a 
formal ASD diagnosis, an age range between 3 and 18 years and that the child attend an educational 
service and reside in the Western Cape Province. Children with comorbid medical, psychiatric and 
neurodevelopmental conditions were not excluded from the study.  
Alpha School for Autistic Children in Cape Town has over 60 learners between the ages of 4 and 18 
years. Vera School for Autistic Children has approximately 100 learners. All children were diagnosed 
with ASD following an assessment by a multidisciplinary professional team which included a clinical 
psychologist. Children were diagnosed with ASD based on DSM-IV criteria and age appropriate rating 















Cape Town metropolitan area and to a lesser extent other regions within the Western Cape 
Province. Autism Action South Africa is an independent organisation with 300 registered members. 
Through Autism Action South Africa, parents of children who met inclusion criteria were invited to 
participate in the survey. Parents of learners attending Alpha and Vera Schools were issued with 
paper copies of the survey questionnaires for self-completion whilst survey participation requests 
were sent out via email to members of the Autism Action database.  
Outcome measures 
A survey questionnaire was adapted with permission from the author from that used in previous 
point prevalence studies of psychotropic medication use for ASD (Aman et al 1995). Data was 
collected on age, gender, ethnicity, total income, current medication use (including prescribed and 
OTC), special diet use, medication prescriber, indication for medication and presence of medical and 
psychiatric co-morbidity. For the purpose of this study OTC medications were defined as any non-
prescription preparation taken by the child for any health promotion or treatment purposes. 
Questions about level of the child’s intellectual disability and severity of autism were excluded from 
the questionnaire because of parental under reporting found in previous studies (Aman et al 
1995).The questionnaire was developed in English and translated into Afrikaans where the latter was 
the parents’ home language.  
Participating parents completed the Nisonger Child Behaviour Rating Form (NCBRF) a standardized 
instrument for assessing behaviour in children and adolescents with intellectual and developmental 
disabilities. There are currently no child behaviour rating scales that have been adapted and 
validated in the South African population. The NCBRF has been validated in the United States and 
the subscales correspond highly with those of the Autism Behaviour Checklist (Aman et al 1996, 
Tasse et al 1996). It has been used in several international medication prevalence studies in the ASD 
population. The NCBRF has 10 social competence items. These are rated on a four-point Likert scale 















Compliant/Calm and Adaptive/ Social. The problem behaviour section consists of 66 items. These are 
rated on a Likert Scale from [0] if the behaviour did not occur or was not a problem to [3] if the 
behaviour occurred a lot or was a severe problem. The items are distributed on 6 subscales: Conduct 
Problem, Insecure/ Anxious, Hyperactive, Self-Injury/ Stereotypic, Self-Isolated/ Ritualistic and 
Overly Sensitive. The NCBRF has been translated into Afrikaans and it has been linguistically 
validated by the MAPI Institute (MAPI Institute 2009).  
Data Analysis 
Statistical analysis was conducted using SSPS Statictics 19. Anticonvulsants were grouped as mood 
stabilisers if epilepsy was not present. Point prevalence of medications was determined using 
frequency counts. Logistic regression analysis was used to determine whether there was any 
relationship between medication use and demographic (school, age, income, ethnicity) or 
behavioural measures (NCBRF subscales). For the analysis, income was grouped into two ranges, R0-
R15999 and >R16000 per month, and R0-R15999 was used as the reference range. White and asian 
ethnicities were grouped together and used as the reference for the ethnic groupings.  
Results 
Response rates to the survey were 38% and 37% for Alpha School and Vera School respectively. 
There were 6 responses from the Autism Action data base. Of the 65 children, 35.4% attended Alpha 
School, 55.4% attended Vera School and 9.2% other schools. The demographic data of the children 
including a comparison between the schools is shown in Table 1. The majority of children (92.3%) 
were male, with a range of ethnicities and incomes. The median age of the children was 9 years 
(range 5-18 years). A total of 13.8% of children in this sample had been diagnosed with co-morbid 
psychiatric disorders, namely attention deficit hyperactivity disorder (ADHD) (9.2%), depression 
(1.5%), anxiety (1.5%), bipolar mood disorder (1.5%) and obsessive compulsive disorder (OCD) 















the most commonly reported being allergic rhinitis (13.8%), asthma (13.8%), epilepsy (7.7%), 
sinusitis (4.6%), and eczema (3.1%). Of the total 24.6% of children were taking medications for a 
physical illness (Table 2).  
A total of 24.6% of children took psychotropic medications. There was a difference in psychotropic 
medication use between the schools (see Table 3), with 27.8% of children from Vera School and 
8.7% of children from Alpha School taking psychotropic medications. This difference was not 
statistically significant. Antiepileptics used for epilepsy were excluded from the psychotropic total, 
that is they were not rated as mood stabilisers. Antipsychotics (16.9%) were the most commonly 
prescribed psychotropics followed by stimulants (6.2%), antidepressants (6.2%) and mood stabilisers 
(3.1%). Risperidone was by far the most commonly reported prescribed psychotropic medication, 
being used by 15.4% of children. 
Respondents reported that psychotropics were prescribed for a range of symptoms. The most 
common indication reported for any psychotropic medication used was problem behaviour (12.3%) 
followed by inattention and hyperactivity (10.8%), anxiety (4.6%), sleep difficulty (3.1%), mood 
stabilisation (3.1%), depression (1.5%) and psychotic symptoms (1.5%). In some cases several 
psychotropics were prescribed for a general symptom such as ‘problem behaviour’ while in other 
cases a specific drug had been prescribed for a specific indication such as inattention or depression. 
Of the antipsychotics, the most commonly prescribed in this sample, risperidone had been 
prescribed for a range of difficulties including problem behaviour, sleep difficulties, anxiety 
symptoms, attention problems and mood symptoms. One child was taking risperidone combined 
with quetiapine to target problem behaviour and ADHD. The other antipsychotic reportedly 
prescribed was sulpiride which had been prescribed to target psychotic symptoms. In all cases of 
reported methylphenidate use the indication for prescription was symptoms of inattention or ADHD. 
One child was taking atomoxetine in combination with methylphenidate for symptoms of 















and poor attention in another. Sertraline was prescribed for anxiety and imipramine for problem 
behaviours. Lithium and sodium valproate were prescribed to stabilise mood and target problem 
behaviours. Sodium valproate was also used as an anticonvulsant in three children with epilepsy. 
Lamotrigine and topiramate had been prescribed as anticonvulsants and not mood stabilisers. 
Of the children taking any physical or psychotropic medication 29.6% reported current side effects 
on treatment. Many children were taking several medications in combination and respondents did 
not always identify which specific treatment was causing a side effect. Several respondents reported 
that they did not know whether their children were experiencing side effects on medication. The 
range of side effects reported included drooling (combination of epilim, topiramate, clobezam), 
vomiting (risperidone), sedation (risperidone), increased appetite (epilim), muscle spasms 
(risperidone), palpitations (methylphenidate) and emotional dysregulation (risperidone). Weight 
gain was reported as a side effect in five children. In three of the children weight gain was 
specifically attributed to a single drug namely risperidone, epilim and corticosteroids. For the other 
two children the combination of medications reported as responsible for weight gain were epilim, 
quetiapine and risperidone; and methylphenidate, atomoxetine and risperidone. Five of the ten 
children taking the most commonly prescribed psychotropic, risperidone, experienced side effects; 
although in two of these children it was taken in combination with other dugs and the respondents 
were unable to identify specifically which drug was responsible for the side effect. Side effects that 
were attributed specifically to risperidone were weight gain, sedation, muscle spasms, vomiting and 
emotional dysregulation. One child with comorbid diagnoses of OCD and bipolar mood disorder had 
previously been prescribed ziprasidone for behaviour problems but this had been stopped because 
of side effects of nausea, abdominal pain and sedation. At this time the child was found to have a 
fatty liver. 
OTC medication and special diet use are summarised in Table 4. Of the total number of children 40% 















use between the schools with 55.6% of children from Vera School and 13% of children from Alpha 
School taking OTC medications. This difference is not statistically significant. Of the total number of 
children, 16.9% were taking one OTC preparation, 13.8% two preparations and 9.2% three or more 
OTC preparations. A range of OTC medication was used including vitamins, minerals, dietary 
supplements, probiotics and homeopathic preparations. None of the children taking these 
preparations reported any side effects. Multivitamins (18.5%) and omega 3 and or 6 preparations 
(16.9%) were the most commonly taken preparations. A particular omega 3 and 6 brand, Eye Q, was 
used by 9.2% of the children. Gluten and casein free diets were the most commonly reported special 
diets. Three respondents reported that their children had tried special diets previously; including 
gluten, casein and sugar free diets; but that these had been stopped because no change in behaviour 
was seen. 
The majority of medications and OTC preparations were prescribed or recommended by 
psychiatrists (22.5%) followed by general practitioners (12.5%), paediatricians (12.5%) and self-
prescriptions (20%). A range of other prescribers were reported including neurologists (7.5%), 
homeopaths (5%), nutritionists (2.5%), pharmacists (2.5%) and social workers (2.5%). 
Following adjusted and unadjusted model logistic regressional analyses, none of the variables 
analysed were shown to predict psychotropic medication use (Table 5). This differed from OTC 
medications in which unadjusted logistic regressional analysis showed the following variables 
predicted OTC medication use: income, ethnicity, and Compliant/Calm subscale of the NCBRF (Table 
6). In the adjusted model only ethnicity predicted OTC medication use. When compared to the 
white/asian ethnic group, black (O.R = 0.03, 95% C.I 0.0-0.86) or coloured ethnic groupings (O.R 

















This study aimed to investigate the prevalence and patterns of medication use in a sample of 
children and adolescents living with ASD in the South African context. The study findings 
demonstrate a high prevalence of psychotropic medication use in children with ASD in a South 
African population. This is consistent with findings from international studies. However, the 
prevalence rate in this sample was slightly lower (25%) than estimates reported in international 
samples (30-60%). This sample included school going children only and in South Africa children with 
severe or  profound disabilities are excluded from the education system. Severity of autism has been 
shown to predict medication use (Rosenberg et al 2010) and it is possible that a sample including 
lower cognitively functioning children may have shown higher rates of psychotropic medication use. 
This lower rate may also reflect poorer access to mental and other health care services in South 
Africa. Types of medications prescribed were similar to previous studies with antipsychotics, 
antidepressants and stimulants being the most commonly prescribed psychotropics as reported in 
the international literature. Risperidone was by far the most commonly prescribed agent which may 
reflect confidence in its FDA approval for use in autism. The atypical antipsychotics are not however 
without side effects with recent studies showing an increased risk of diabetes in children prescribed 
these medications (Andrade et al 2011). Five of the ten children taking medications that included 
risperidone reportedly experienced side effects and in three of the cases the side effects were 
directly attributed to risperidone. Of the five children who reported weight gain as a side effect of 
any medication three were taking risperidone, although in two cases this was in combination with 
other medications. Risperidone was prescribed for a range of other indications beyond its FDA 
approval including anxiety and mood symptoms and inattention. 
The prevalence rates of OTC medications were high (40%) in this sample with 9.2% of the children in 
the sample taking three or more agents. This finding is also in keeping with international literature. 















chronic illnesses and disabilities compared to the general population (Hanson et al 2007). Prevalence 
rates of 54% for biologically based alternative therapies, such as modified diet and vitamin 
supplements, have been reported in children with ASD (Hanson et al 2007). There is currently 
insufficient evidence to support the use of OTC medications or special diets in the treatment of ASD. 
These medications can be costly. Interestingly income did not predict OTC use but ethnicity did, with 
the white/asian ethnic group being more likely to take OTC preparations than the black or coloured 
groups. This may reflect differences in cultural beliefs around OTC medications. Traditional 
medicines were not specifically asked about in the survey questionnaire. These may not have been 
considered to be over the counter preparations by participants and may therefore have been 
underreported.  
Response rates to the survey were low in spite of multiple contacts. Survey handouts at the schools 
received a far better response than the emailed survey request. People may be more likely to 
complete a survey if they receive a paper copy. Encouragement from staff at the schools may also 
account for this difference. Medication use in children with ASD is a very sensitive issue and parents 
may be reluctant to divulge information about medications or OTC preparations that their children 
are taking. The majority of respondents’ children were male (92%). Previous prevalence surveys in 
the ASD population have also shown a high percentage, usually greater than 80%, of males in the 
sample. Boys are three to four more times likely to be diagnosed with autism than girls (Steyn and Le 
Couteur 2003) but this alone does not account for the high percentage of male children in this and 
other studies. Both schools in this study have a higher proportion of male learners with Alpha School 
having a male to female learner ratio of 4:1 and Vera School a ratio of 8:1. The higher proportion of 
male learners may in part explain the higher proportion of male children in this sample. 
There are several limitations to this study. The sample was drawn from school going children only 
and therefore excluded lower functioning children with ASD. There were very few respondents from 















therefore also not well represented in the sample. The small sample size may have limited the ability 
of the study to demonstrate statistical significance of the some of the findings, including behaviour 
scores predicting medication use. The NCRBF has not been adapted and validated in the South 
African context. The demographic questionnaire and NCBRF have not been translated into isiXhosa 
and this may have limited participation of Xhosa speaking participants. Finally, the study was 
undertaken in a two schools in one province and the findings may not be generalisable to other 
South African populations. 
Notwithstanding the limitations, this pilot study provides an insight into medication use in a South 
African ASD population and serves as a basis for further research. Larger sample sizes would serve to 
validate the above findings. As elsewhere, it is important to inform South African health 
professionals, families and educators, especially those working in low resource settings, of the 
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Table 1: Demographics of Children in the Study Population 
 Total Alpha School Vera School Other schools 
 N  %  Md R N  %  Md R N  %  M SD N  %  M SD 
Respondents 65 100   23 35.4   36 55.4   6 9.2   
Variables                 
Gender                 
Male 60 92.3   23 100   31 86.1   6 100   
Female 5 7.7   0 0   5 13.9   0 0   
Age in years   9 5-18   10 5-18   10.9 3.5   8.0 2.8 
Ethnicity                 
Asian 3 4.6   0 0   3 8.3   0 0   
Black African 10 15.4   6 26.1   2 5.6   2 33.3   
Coloured 27 41.5   15 65.2   10 27.8   2 33.3   
White 25 38.5   2 8.7   21 58.3   2 33.3   
Income                  
R501-R2500 10 15.4   8 34.8   1 2.8   1 16.7   
R2501-R6000 12 18.5   8 34.8   4 11.1   0 0   
R6001-R16000 11 16.9   4 17.4   6 16.7   1 33.3   
R16001-R30000 13 20   1 4.3   10 27.8   2 33.3   
R30000+ 15 23.1   1 4.3   12 33.3   2 33.3   
 
Income= Family income per month 
M= Mean 
Md= Median 


















Table 2: Physical illness and Physical Medications in Children in the Study Population 
 N  %      
Medical illness  
Total 26 40  
Epilepsy 5 7.7  
Allergic rhinitis 9 13.8  
Sinusitis 3 4.6  
Asthma 9 13.8  
Eczema 2 3.1  
Constipation 3 4.6  
Hypothyroidism 1 1.5  
Cardiac anomaly 1 1.5  
Cerebral palsy 1 1.5  
 Physical Medication  
Total 16 24.6  
Lamotrigine 2 3.1  
Clobazam 1 1.5  
Topiramate 1 1.5  
Sodium valproate 3 4.6  
Asthavent 4 6.2  
Beclomethasone 3 4.6  
Nasal spray 2 3.1  
Cetirizine 2 3.1  
Montelukast 1 1.5  
Prednisone 1 1.5  
Laxative 3 4.6  
























Psychotropic use N  %  N  %   N  %   N  %     
Total psychotropic medication use 16 24.6 2 8.7 10 27.8 4 66.7 
Total antipsychotics 11 16.9 2 8.7 7 19.4 2 33.3 
Risperidone 10 15.4 2 8.7 6 16.7 2 33.3 
Sulpiride 1 1.5 0 0 1 2.8 0 0 
Quetiapine 1 1.5 0 0 1 2.8 0 0 
Total stimulants 4 6.2 1 4.3 1 2.8 2 33.3 
Methylphenidate 4 6.2 1 4.3 1 2.8 2 33.3 
Atomoxetine 1 1.5 0 0 0 0 1 16.7 
Total antidepressants 4 6.2 0 0 2 5.6 2 33.3 
Fluoxetine 2 3.1 0 0 1 2.8 1 16.7 
Sertraline 1 1.5 0 0 1 2.8 0 0 
Imipramine 1 1.5 0 0 0 0 1 16.7 
Total mood stabilisers 2 3.1 0 0 2 5.6 0 0 
Lithium 1 1.5 0 0 1 2.8 0 0 
Sodium valproate 2 3.1 0 0 2 5.6 0 0 
Indication for psychotropics         
Problem behaviour 8 12.3 1 4.3 5 13.9 2 33.3 
Inattention and hyperactivity 7 10.8 1 4.3 3 8.3 3 50 
Sleep difficulty 2 3.1 1 4.3 1 2.8 0 0 
Anxiety  3 4.6 0 0 3 8.3 0 0 
Depression 1 1.5 0 0 1 2.8 0 0 
Mood stabiliser 2 3.1 0 0 1 2.8 1 16.7 

























Diet and OTC medication use N  %      N  %   N  %      N  %      
Special Diet 10 15.4 3 8.7 7 19.4 1 16.7 
Total number of OTC medications 26 40 3 13 20 55.6 3 50 
Number of OTC per child         
1 11 16.9 2 8.7 8 22.2 1 16.7 
2 9 13.8 0 0 8 22.2 1 16.7 
3 3 4.6 1 4.3 2 5.6 0 0 
More than 3 3 4.6 0 0 2 5.6 1 16.7 
Type of OTC medication         
Multivitamin 12 18.5 3 13 8 22.2 1 16.7 
Vitamin C 2 3.1 0 0 2 5.6 0 0 
Vitamin B 3 4.6 0 0 3 8.3 0 0 
Omega 3 and or 6 all 11 16.9 0 0 9 25 2 33.3 
Eye Q (Omega 3 and 6 brand) 6 9.2 0 0 4 11.1 2 33.3 
Melatonin 2 3.1 0 0 2 5.6 0 0 
Zinc 2 3.1 0 0 1 2.8 1 16.7 
Magnesium 3 4.6 0 0 2 5.6 1 16.7 
Folic acid 2 3.1 0 0 2 5.6 0 0 
Calcium 1 1.5 0 0 1 2.8 0 0 
Iron 1 1.5 0 0 0 0 1 16.7 
Dietary supplement 5 7.7 0 0 5 13.9 0 0 
Probiotics 3 4.6 0 0 2 5.6 1 16.7 
Homeopathic preparations 3 4.6 0 0 3 8.3 0 0 















Table 5: Regressional Analysis of Variables Predicting Psychotropic Medication Use in the 
Study Population 
 Unadjusted Model Adjusted Model 
Predictor P O.R (95% C.I) P O.R (95% CI) 
School Vera (Reference)  1.0  1.0 
School Alpha 0.09 0.24 (0.05-1.26) 0.28 0.05 (0-11.81) 
School other 0.08 5.2 (0.82-33) 0.06 1.12 (0.53-2.37) 
Age 0.16 1.13 (0.95-1.34) 0.14 1.56 (0.86-295) 
Income R0-R15999 (Reference)  1.0  1.0 
Income R16000 + 0.71 0.8 (0.24-2.65) 0.07 0 (0-3.08) 
Ethnicity White/Asian (Reference)  1.0  1.0 
Ethnicity Black 0.15 0.2 (0.02-1.82) 1 0 
Ethnicity Coloured 0.16 0.41 (0.12-1.42) 0.17 0 (0-45.89) 
NCRBF Behaviour     
  Compliant Calm 0.52 0.93 (0.76-1.15) 0.17 0.59 (0.28-1.25) 
  Adaptive Social 0.6 0.94 (0.74-1.19) 0.86 1.07 (0.49-1.34) 
  Conduct Problem 0.7 1.02 (0.94-1.09) 0.09 0.81 (0.64-1.03) 
  Insecure Anxious 0.34 1.04 (0.96-1.12) 0.3 0.81 (0.55-1.2) 
  Hyperactive 0.1 1.1 (0.98-1.23) 0.09 1.81 (0.9-3.65) 
  Self Injury Stereotypy 0.44 1.07 (0.9-1.26) 0.14 1.67 (0.85-3.3) 
  Self Isolated Ritualistic 0.89 1 (0.89-1.15) 0.92 1.02 (0.68-1.52) 
  Overly Sensitive 0.89 1.01 (0.85-1.21) 0.39 1.46 (0.62-3.44) 
     
O.R = Odds Ratio 
















Table 6: Regressional Analysis of Variables Predicting OTC Medications in the Study 
Population 
 Unadjusted Model Adjusted Model 
Predictor P O.R (95% CI) P O.R (95% CI) 
School Vera (Reference)  1.0  1.0 
School Alpha 0 0.12 (0.03-0.48) 0.08 0.12 (0.1-1.25) 
School other 0.8 0.9 (0.12-4.5) 0.18 9.78 (0.36-264.12) 
Age 0.22 1.1 (.94-1.29) 0.98 1.0 (0.78-1.28) 
Income R0-R15999 (Reference)  1.0  1.0 
Income R16000 + 0.01* 5.25 (1.5-18.38) 0.2 0.17 (0.1-2.57) 
NCRBF Behaviour     
  Ethnicity White/Asian (Reference)  1.0  1.0 
  Ethnicity Black 0.01* 0.53 (0.01-0.48) 0.04 * 0.03 (0.0-0.86) 
  Ethnicity Coloured 0* 0.14 (0.04-0.45) 0.02 * 0.09 (0.01-0.62) 
  Compliant Calm 0.05* 0.81 (0.66-1.0) 0.71 0.93 (0.63-1.36) 
  Adaptive Social 0.07 0.81 (0.65-1.02) 0.1 0.64 (0.37-1.09) 
  Conduct Problem 0.44 1.03 (0.97-1.1) 0.67 0.96 (0.81-1.14) 
  Insecure Anxious 0.35 1.03 (0.96-1.11) 0.81 1.02 (0.84-1.24) 
  Hyperactive 0.1 1.09 (0.99-1.2) 0.65 1.06 (0.82-1.36) 
  Self injury Stereotypy 0.42 1.07 (0.91-1.24) 0.84 0.97 (0.69-1.36) 
  Self isolated Ritualistic 0.4 1.05 (0.94-1.18) 0.87 0.98 (0.74-1.29) 
  Overly Sensitive 0.19 1.11 (0.94-1.31) 0.2 1.3 (0.87-2) 
     
* Statistically significant difference at P ≤ 0.05 
O.R=Odds Ratio 
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THE NISONGER CHILD BEHAVIOR RATING FORM 
PARENT VERSION: SCORE SHEET I 
Child's Name: _ _______ ___________ -'C.whild's Date of Birth: __ -'-__ '--__ 
month day year 
Rater's Name: _____________ ________ -'Da""'te of Rating: __ -'-_ _ '--__ 
month day year 
Relation of Rater to Child: .. parent [I) .. other [9J: _____________________ _ 
(please specify) 
INSTRUCTIONS. Trnnscnbe the rnt:ings from the Nisonger CBRF and write them into the "rating" column next to the 
appropriate item nwnber "#". When all ratings have been transcribed, total the colwnns to obtain the subscale scores. 
" POSITIVE SOCIAL III PROBLEM BEHAVIOR 
Compliant I Adaptive Conduct Insecure I Self-Injury I Self-Isolated I Overly 
Calm Social Problem Anxious Hypcrnctive Stercotypic Ritua listic Sensitive 
# rating # rating # rating # rating # rating # rating # rating # rating 
I 2 2 t6 9 6 I 3 
3 5 4 21 J3 II 18 5 
4 7 7 23 19 22 25 14 
6 8 8 30 24 32 29 I S 
9 Total 10 3J 33 43 37 20 
10 12 34 35 53 47 Tolal -
Total 17 41 38 58 49 ---
26 42 39 Total 64 
36 44 46 Total -
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